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Summary 
More than 300 billion blood cells are being replaced daily in a process called 
hematopoiesis. Hematopoiesis is orchestrated by hematopoietic stem cells (HSCs) 
residing in the bone marrow. HSCs produce multipotent and lineage-restricted 
progenitors, that are responsible for the supply of mature blood cells. Production of 
blood cells is governed by hematopoietic growth factors that are required for the 
survival and proliferation of blood cells at all stages of development. Mutations in 
genes responsible for the regulation of this fine-tuned system cause aberrant 
proliferation of different blood compartments. Myeloproliferative neoplasms (MPN) 
are characterized by the abnormal expansion of erythroid, megakaryocytic, and 
myeloid lineages, that is caused either by somatic mutations or by germline 
mutations transmitted through Mendelian inheritance within the family. The main 
topic of my doctoral research was the investigation of two distinct pedigrees 
diagnosed with erythrocytosis and thrombocytosis, respectively. 
Erythrocytosis occurred in ten individuals of Norwegian family that presented 
elevated hemoglobin and erythropoietin (EPO) serum levels. We performed 
genome-wide linkage analysis using SNP arrays coupled with targeted sequencing 
and identified a heterozygous single base deletion (ΔG) in exon 2 of the EPO gene 
as the sole candidate gene mutation in affected family members. EPO stimulates 
the proliferation of erythrocyte progenitors and prevents their apoptosis in order to 
produce mature erythrocytes. Surprisingly, ΔG introduces a frame-shift that 
generates a novel, 51-residue long polypeptide, which would predict a loss of 
erythropoietin function, and is at odds with the erythrocytosis phenotype. To 
elucidate the mechanism by which the loss-of-function mutation causes gain-of-
function phenotype, we utilized the CRISPR/Cas9 genome editing to introduce the 
ΔG mutation into Hep3B cells, a human hepatoma cell line that expresses EPO. We 
found that cells with ΔG mutation produce excessive amounts of biologically active 
EPO and reproduces the observation form the affected family members. On the 
molecular level, in addition to the known transcript originating from the physiologic 
promoter (P1), we identified novel transcripts that initiate in intron 1 of EPO from a 
putative alternative promoter (P2). Further functional analysis of P2 mRNAs 
revealed an alternative translational start site in exon 2 that P2 transcripts use to 
produce a biologically active EPO protein, by fusing a novel N-terminus to the EPO 
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coding sequence through the ΔG single base deletion. Our data demonstrate for the 
first time, that a mutation in EPO cause familial erythrocytosis and explain how the 
ΔG mutation results in a gain-function phenotype. 
I also investigated a pedigree with autosomal-dominant. Targeted sequencing 
identified a novel activating mutation in exon 3 of the thrombopoietin (THPO) gene, 
a single nucleotide G->T substitution. Thrombopoietin stimulates the production of 
platelets from megakaryocytes. THPO expression is regulated on the translational 
level by seven upstream open reading frames (uORF1-7) in the exons 1-3 of THPO 
mRNA, that are interfering with the translation of TPO. G>T mutation maps to the 
Kozak sequence of the uORF7, the most critical negative regulator of TPO 
translation. We performed TPO overexpression and in vitro translation experiments 
to demonstrate that the G>T mutation disrupts the negative regulation governed by 
uORF7 and allows for increased translation of THPO protein coding sequence, 
ultimately causing thrombocytosis.  
Collectively, in both studies we identified novel gain-of-function mutations in 
hematopoietic growth factors, that act at different steps of gene expression and 
result in the dysregulated production of EPO and TPO, causing erythrocytosis and 
thrombocytosis in respective pedigrees.  
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1 Introduction 
 
1.1 Hematopoiesis 
 
The human body is a complex organism composed of 1013 to 1014 human cells. 
Strikingly, as illustrated in Figure 1, around 93% of cells are coming from a single 
tissue – blood (Sender et al., 2016). This tissue is composed of more than ten 
different cell types that perform various functions, ranging from oxygen and nutrient 
transport to immune surveillance. Daily turnover of the blood cells is enormous. 
Each day, more than 300 billion cells (Notta et al., 2016) composed of  2x1011 
erythrocytes (Dzierzak and Philipsen, 2013), 1011 platelets (Kaushansky, 2005) and 
1011 leukocytes (Wirths et al., 2013) are produced in the human bone marrow by 
hematopoietic stem cells (HSCs), and multipotent, lineage-restricted progenitors 
collectively called hematopoietic stem and progenitor cells (HSPCs). 
 
 
 
 
HSCs are the most-studied adult stem cells owing to the properties that allow their 
examination in great detail. First of all, these cells are available from the blood; 
hence their isolation is minimally invasive. Secondly, they are naturally capable of 
extravasating into the tissues and thus withstand immense shear forces. This makes 
the isolation and characterization by flow cytometry available. Lastly, HSCs grow 
single-cell colonies under the proper culture conditions, which allows performing 
Figure 1. The distribution of the number of human cells by cell type depicted as a Voronoi tree map where 
polygon area is proportional to the number of cells.  Adapted from (Sender et al., 2016). 
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clonogenicity assays. The above-described properties made detailed 
characterization of distinct hematopoietic stem cell and progenitor populations 
possible, by combining the surface marker expression patterns with functional tests 
examining self-renewal properties (Akashi et al., 2000; Kiel et al., 2005; Kondo et 
al., 1997; Morrison and Weissman, 1994; Osawa et al., 1996). The exceptional 
capability of HSCs to repopulate mature blood cell lineages was demonstrated by 
the experiment, in which a single stem cell was able to restore the entire 
lymphohematopoietic system of the lethally irradiated mouse (Osawa et al., 1996).  
Since 1957, hematopoietic stem cell transplantation is the prime example of success 
in the field of regenerative medicine (Thomas et al., 1957). It has become a life-
saving and routine treatment for patients suffering from blood disorders or 
hematological malignancies. HSC transplantation reaches up to 22,000 transplants 
in the US and 40,000 in Europe annually (Norkin and Wingard, 2017; Passweg et 
al., 2016). 
 
1.1.1 Embryonic hematopoiesis 
 
Development of embryonic hematopoietic system starts once the embryo reaches 
a size, which makes the delivery of oxygen and other factors by the simple diffusion 
impossible. Hematopoiesis first takes place the extraembryonic tissues – yolk sac, 
allantois, and placenta. In mice, embryonic hematopoiesis moves from 
extraembryonic tissues into the aorta-gonad-mesonephros (AGM) region. AGM and 
placenta are also the regions, where first cells with the properties similar to the adult 
HSCs are produced (Gekas et al., 2005; Ivanovs et al., 2011; Medvinsky and 
Dzierzak, 1996; Müller et al., 1994; Ottersbach and Dzierzak, 2005). Source of 
HSCs in the mouse embryo is a specialized subset of vascular endothelium that 
acquires hematopoietic potential, called hemogenic endothelium (Eilken et al., 
2009). This observation could be later also confirmed in the developing zebrafish 
embryos (Bertrand et al., 2010; Kissa and Herbomel, 2010).  
Embryonic HSCs also have different properties in comparison to their adult 
counterparts – they are actively cycling and regenerate hematopoiesis faster and 
more robustly in order to establish a functional hematopoietic system in a developing 
embryo. Around day E11, murine HSCs migrate from the hemogenic endothelium 
to the fetal liver, the major site of hematopoiesis during embryonic development. 
Later on, at day E16.5 they migrate to the bone marrow (Coşkun et al., 2014). Bone 
8
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marrow and to the lesser extent also spleen, become the primary sites of 
hematopoiesis in the adult organism. First, bone marrow of long bones, such as tibia 
and femur, is in charge of generating blood cells. Later, the production gradually 
shifts to vertebrae, sternum, ribs, and cranium (Figure 2).  
 
 
 
 
 
 	
1.1.2 Adult hematopoiesis 
 
The hematopoietic system is hierarchically organized. At the top of the hierarchy sit 
HSCs and number of progenitor stages with increasingly restricted lineage potential 
down to the mature blood cells are located below (Figure 3). Long-term HSCs (LT-
HSCs), robustly self-renew and are able to reconstitute all blood lineages upon 
transplantation into lethally irradiated recipients, thus fulfilling the formal criteria of 
the stem cell definition: self-renewal, and differentiation potential (Benveniste et al., 
2010; Osawa et al., 1996). Functional LT-HSCs in murine models are defined as 
having the ability to reconstitute all blood cell lineages for more than 24 weeks after 
the transplantation and, to repopulate the secondary recipients (Benveniste et al., 
2010). Many studies used various surface markers to characterize different cell 
Figure 2. Hematopoietic development in the embryonic, fetal and postnatal stage of development. Blue 
curves display the relative contribution of the different anatomical sites to the hematopoiesis during ontogeny. 
Adapted from (Kaushansky et al., 2016). 
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populations and identified, that stem cell activity in mouse lies within so-called LSK 
(Lin-/Sca-1+/c-kit+) population (Figure 3). 
 
 
 
 
 
 
 
LSK population represents ~ 0.06% of the total bone marrow cells and contains cells 
with the expression of immature multipotent cell markers CD117 (c-kit) and Sca-1, 
and lack of the expression for the markers of mature lineages (Lin) (Morrison and 
Weissman, 1994; Okada et al., 1992; Spangrude et al., 1988; Uchida, 1992) LT-
HSC population is very rare, and approximately one in thirty LSK cells is LT-HSC 
(0.002% in BM). The most widely used approach to obtain murine HSCs relies on 
enriching for LSK/CD150+/CD48-/CD34low population, in which at least 50% of cells 
are true LT-HSCs with long-term repopulating potential (Kiel et al., 2005). An 
Figure 3. Hierarchy of the hematopoietic system. Long-term hematopoietic stem cells (LT-HSC) that are 
characterized by the self-renewal and differentiation potential sit at the apex of the hierarchy. Surface markers 
for prospective isolation of different populations are shown for both mouse and human system (boxed 
combinations on the right). Bold arrows display established, and thin arrows display alternative differentiation 
routes. Abbreviations used: HSC, hematopoietic stem cell; MPP, multipotent progenitor; LT-, long-term; IT-, 
intermediate-term ; ST-, short-term; LMPP, lymphoid-primed MPP; ELP, early lymphoid progenitor; CLP, 
common lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte–macrophage progenitor; 
MEP, megakaryocyte–erythrocyte progenitor; CDP, common dendritic progenitor; MDP, monocyte–dendritic 
cell progenitor; NK, natural killer cell.  Adapted from (Rieger and Schroeder, 2012). 
		
10
Genetic studies of hereditary myeloproliferative disorders	| Jakub Zmajkovic		
alternative strategy to cell surface markers is the use of functional properties of 
HSCs to isolate them. HSCs are equipped with very active ATP-binding cassette 
(ABC) transporters, a type of an efflux system used to protect themselves from toxic 
molecules. HSCs reside in the so-called side population (SP) that effectively 
transport cell-penetrating dyes such as Hoechst 333420 (Goodell, 1996), or 
Rhodamine123 dye (Bertoncello et al., 1985) out of the cell. 
HSCs need proper microenvironment in order to maintain their functionality. In the 
bone marrow, they reside in the perivascular niche. Perivascular niche is localized 
in the proximity of sinusoidal blood vessels that provide support for hematopoietic 
stem and progenitor cells (Crane et al., 2017; Kunisaki et al., 2013; Nombela-Arrieta 
et al., 2013). It also controls quiescence, proliferation, and differentiation of HSCs. 
Under steady-state conditions, ~ two-thirds of HSCs are kept in the quiescent state 
(Passegué et al., 2005). 
HSCs differentiate into a cascade of progenitor cell types with declining multilineage 
potential before unilineage commitment occurs (Figure 3) (Adolfsson et al., 2005; 
Kondo et al., 1997; Wilson et al., 2008). Unilineage commitment is the point, at which 
the cell becomes irreversibly restricted to a defined fate and loses the potential to 
differentiate. Multiple studies demonstrated the heterogeneity of HSPC 
compartment and challenged the established hierarchical hematopoietic lineage 
tree (Figure 4A). For example, a study by Adolfsson and colleagues identified, that 
LSK/CD34+/Flt3+ population failed to produce erythroid and megakaryocytic 
colonies, and termed it lymphomyeloid-restricted progenitors (LMPP) (Adolfsson et 
al., 2005) (Figure 4B).  
In vivo lineage tracing study showed that common myeloid progenitor (CMP) 
population is highly heterogeneous, and the divergence between myeloid cells and 
erythrocytes starts already within the multipotent progenitor pool (MPP) (Perié et al., 
2015). Another study, employing single-cell transplantation experiments suggested 
the so-called myeloid bypass model. In this model, a myeloid-restricted population 
(MyRP) produced by HSCs can clonally expand and is responsible for the 
generation of myeloid cells (Figure 4C) (Yamamoto et al., 2013).  
Several studies advocate the existence of megakaryocyte-primed HSCs, that are 
associated with age and mainly responsible for the generation of megakaryocytes 
and platelets, especially under the stress conditions such as inflammation (Grover 
et al., 2016; Haas et al., 2015; Sanjuan-Pla et al., 2013). 
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All these studies have used lethal irradiation and in their experimental setup. 
Irradiation is known to create a cytokine release syndrome, that favors engraftment. 
Thus, these models represent stress-induced hematopoiesis. To overcome this 
limitation, several groups developed alternative approaches to monitor unperturbed, 
steady-state hematopoiesis (Busch et al., 2015; Rodriguez-Fraticelli et al., 2018; 
Sun et al., 2014). These studies showed that steady-state hematopoiesis is driven 
by a large number of long-lived progenitors rather than the small number of 
multipotent hematopoietic cells (Busch et al., 2015; Sun et al., 2014), and that 
megakaryocyte lineage arises largely independently of other hematopoietic fates 
(Rodriguez-Fraticelli et al., 2018). 
Human HSCs express CD34 molecules on their surface and together with the lack 
of CD38 and lineage markers define human HSPC population: CD34+/CD38-/Lin-. 
However, due to the technical limitations, purification of human HSPC compartment 
is far less advanced and thus CD34+/CD38-/Lin- population contains <1% of 
functional HSCs. By adding further specific surface markers, scientists were able to 
further enrich the HSPC population to about 15% (Notta et al., 2011). It is important 
to mention that the abundance of human HSCs in the purified fraction may be 
Figure 4. Different models for the lineage commitment. A) The classical model is defined by the cascade in 
which downstream progenitors are more restricted in their differentiation potential. First branching occurs at 
the level of common myeloid progenitors (CMP) and common lymphoid progenitors (CLP). B) A revised model 
incorporating the lymphomyeloid-restricted progenitors (LMPPs) population that has lost the potential to 
produce megakaryocytes and erythroid progenitors (Adolfsson et al., 2005). C) Myeloid bypass model 
suggests the existence of myeloid-restricted progenitors (MyRPs) that are directly derived from LT-HSCs and 
retain self-renewal capacity. This model proposed that self-renewal and differentiation capacity can be 
uncoupled (Yamamoto et al., 2013). Abbreviations: Ery, erythroid; G/M, granulocyte/monocyte; GMP, 
granulocyte/monocyte progenitor; HSC, hematopoietic stem cell; Meg, megakaryocyte; MEP, 
megakaryocyte/erythroid progenitor; MPP, multipotent progenitor. Adapted from (Nimmo et al., 2015). 
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underestimated since murine microenvironment is less permissive for engraftment 
of human HSCs, and therefore new xenograft models are being developed 
(Rongvaux et al., 2014). Human hematopoietic differentiation hierarchy was thought 
to be similar to the murine one (Majeti et al., 2007). However, a recent study 
challenged the existence of oligopotent progenitors using single-cell assays (Notta 
et al., 2016). 
 
1.2 Hematopoietic growth factors and their receptors 
 
Hematopoiesis is regulated by the hematopoietic growth factors that are required 
for the survival and proliferation of blood cells at all stages of the development. 
Growth factors bind to the extracellular domains of cognate receptors, form signaling 
complexes with receptors and induce intracellular signaling events leading to the 
changes in gene expression. Cytokine receptor superfamily is a large group of 
transmembrane receptors that share a typical structure of around 200 amino acids 
in their extracellular domain. This superfamily has been subdivided into 5 families 
based on the characteristic structural motif: type I cytokine receptor family (also 
called hematopoietin receptor family), type II (also known as interferon receptor 
family), tumor necrotic factor (TNF) receptor family, immunoglobulin receptor family, 
and chemokine receptor family. The majority of growth factors that modulate the 
activity of the hematopoietic system bind to the type I cytokine receptor family 
(Figure 5). Lineage-specific growth factors act on a particular blood lineage due to 
the restricted expression of cytokine receptors and include erythropoietin (EPO), 
thrombopoietin (TPO), and granulocyte colony-stimulating factor (G-CSF). 
Multilineage hematopoietic growth factors include granulocyte-macrophage colony-
stimulating factor (GM-CSF), and interleukins. Both type I and type II receptors lack 
catalytic activity and thus require Janus kinase (JAK) proteins that possess 
phosphorylation activity (Figure 5). Erythropoietin and thrombopoietin will be 
discussed further in more detail in the following chapters.  
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1.2.1 Hematopoietic growth factor-induced signaling 	
Hematopoietic cytokines bind to their respective receptors to initiate the cascade of 
signaling events leading to the changes in the expression of target genes. The 
central axis for this signaling is the JAK-STAT pathway, that was discovered by the 
studies on gene induction by interferon (Darnell et al., 1994). Janus kinase family 
consists of four members: JAK1, JAK2, JAK3, and a non-receptor tyrosine kinase 
TYK2, that are differentially activated by different cytokines (Figure 5) (Stark et al., 
1998). All JAK family members have a common domain structure design containing 
four-point-one, ezrin, radixin, moesin (FERM) domain at its N-terminus that 
connects JAKs with the receptors, Src homology 2 (SH2) domain, and JAK-
homology domains 1 (JH1) and 2 (JH2)  (Pearson et al., 2000). JH1 domain locates 
to the C-terminus of the protein and possesses the kinase activity (Shuai et al., 
1993). JH2 is also termed “pseudokinase” domain, as it was originally thought not 
to have any enzymatic activity. However, a study by Ungureanu and others 
Figure 5. Cytokine receptors and JAK kinase family. Type I and type II receptors are classified according to 
the three-dimensional structure of their ligands. These receptors lack intrinsic kinase activity and depend on 
receptor-associated Janus kinases (JAKs) to transmit the signal. Type I cytokine receptor family (also called 
hematopoietin receptor family) binds growth factors that are modulating the activity of the hematopoietic 
system. Type II receptors are mostly bound by interferons and involved in the regulation of the immune 
response. JAK kinase family consists of 4 different kinases (JAK1, JAK2, JAK3, and TYK2) that are 
differentially activated by different cytokines. Adapted from (Quintás-Cardama et al., 2011). 
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demonstrated that JH2 
domain of JAK2 has a weak 
dual- type kinase activity 
(Ungureanu et al., 2011). 
Ligand binding causes the 
receptor dimerization and the 
activation of JAK kinases that 
are constitutively associated 
with the intracellular domains 
of the receptor. JAK kinase 
undergoes a conformational 
change leading to the auto-
phosphorylation of specific 
tyrosine residues. This 
activation promotes the 
recruitment of signal 
transducer and activator of 
transcription (STAT) transcrip-
tion factors that are also phosphorylated by JAK kinases. STAT protein family 
consists of seven members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, 
and STAT6 that share a high degree of homology across several conserved 
domains, including SRC homology 2 (SH2) domain mediating activation and 
dimerization of STATs (Fu and Zhang, 1993; Shuai, 1994), DNA-binding domain  
(Horvath et al., 1995), and a transactivation domain (Shuai et al., 1993). STAT 
phosphorylation causes dimerization through their SH2 domains and subsequent 
translocation to the nucleus, where they bind to the specific promoter DNA 
sequences and activate the transcription of target genes (Figure 6) (Darnell, 1997; 
Levy and Darnell, 2002). In addition, JAK kinases also activate MAPK and PI3K/Akt 
signaling axes. 
The JAK-STAT signaling pathway is negatively regulated predominantly by 
suppressor of cytokine signaling (SOCS) family of proteins, consisting of eight 
members: SOCS1-SOCS7 and cytokine-inducible SH2-containing protein (CISH) 
(Alexander, 2002; Hilton, 2001). SOCS proteins inhibit JAK-STAT signaling through 
distinct mechanisms. SOCS1 binds directly to JAKs via its SH2 domain, hence 
directly inhibiting the JAK activity (Endo et al., 1997; Naka et al., 1997; Starr et al., 
Figure 6. JAK-STAT signaling pathway. The activation of Janus 
kinase (JAK) upon binding of the cytokine to the receptor results 
in the phosphorylation of signal transducer and activator of 
transcription (STAT) proteins that dimerize and translocate to the 
nucleus to take part in the gene transcription activation. Adapted 
from (Shuai and Liu, 2003). 
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1997). SOCS3 needs to bind to the activated receptor in order to exert its inhibitory 
function (Sasaki et al., 2000). Finally, CISH is competing with STATs for the receptor 
binding sites (Yoshimura, 1998).  	
1.2.2 JAK-STAT signaling in hematopoiesis 	
The essential role of JAK2 in hematopoiesis is demonstrated by the embryonic 
lethality of homozygous germline deletion of JAK2, due to the defective 
erythropoiesis (Neubauer et al., 1998; Parganas et al., 1998). JAK2 associates with 
multiple cytokine receptors: erythropoietin receptor (EPOR), thrombopoietin 
receptor (MPL), granulocyte-colony stimulating factor receptor (G-CSFR), 
granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR) and 
interleukin-3 receptor (IL-3R) being the most prominent. Failure of liver progenitors 
from JAK2-deficient mice to respond to the stimulation with EPO, TPO, GM-CSF or 
IL-3 highlights the importance of JAK2 in mediating the cytokine-induced signaling 
(Parganas et al., 1998). 
JAK2 activates STAT1, STAT3, STAT5a, and STAT5b. STAT1-deficient mice do 
not have any developmental abnormalities, but possess an attenuated response to 
viral infections due to the disrupted interferon signaling (Durbin et al., 1996). These 
mice also show delayed erythroid differentiation, decrease in erythroid colony-
forming units (CFU-E), and defective polyploidization of megakaryocytes (Halupa et 
al., 2005; Huang et al., 2007). Constitutional STAT3 deletion caused defects in 
visceral endoderm and resulted in the embryonic lethality (Takeda et al., 1997). 
Further studies of conditional STAT3 deletion found its role in T-cell proliferation and 
innate immunity regulation (Takeda et al., 1998; Welte et al., 2003). STAT5a and 
STAT5b are closely related and partially redundant proteins essential for 
hematopoiesis. STAT5a/STAT5b double knock-out embryos die from severe 
anemia (Teglund et al., 1998), revealing the essential role of STAT5 isoforms in the 
EPOR-mediated antiapoptotic signaling (Socolovsky et al., 1999). 
Erythropoietin signaling depends on the JAK2-STAT5 axis since mice lacking the 
expression of EPO receptor (Wu et al., 1995), JAK2 (Neubauer et al., 1998; 
Parganas et al., 1998), or STAT5 (Teglund et al., 1998) show inefficient 
erythropoiesis and embryonic lethality. Both JAK2-STAT3 and JAK2-STAT5 
pathways mediate thrombopoietin signaling (Miyakawa et al., 1996). Granulocytic 
16
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differentiation via G-CSF/G-CSFR axis is mostly transmitted through JAK1 and only 
to a lesser extent through JAK2 (Shimoda et al., 1997). 
In 2005, four groups independently reported the discovery of a gain-of-function 
mutation in JAK2 in patients with myeloproliferative neoplasms (Baxter et al., 2005; 
James et al., 2005; Kralovics et al., 2005; Levine et al., 2005) The mutation is a 
single nucleotide G®T transversion that results in a change from valine to 
phenylalanine at the position 617 (V617F). This substitution disrupts the inhibitory 
activity of JH2 pseudokinase domain, that has significant homology to the tyrosine 
kinase domain (JH1) and possess a weak dual-type kinase activity (Ungureanu et 
al., 2011). As a consequence, JH1 domain is constantly activated and hematopoietic 
cells do not depend anymore on the cytokine signaling to instruct their proliferation. 
Noteworthy, the disruption of ATP binding site in the pseudokinase domain JH2 of 
wildtype JAK2 has a minimal effect. However, it can suppress the hyperactivation 
of mutated JAK2 (Hammaren et al., 2015).  
 
1.3 Erythropoiesis  	
Red blood cells perform an essential role in maintaining the existence of all 
vertebrate organisms, owing to their oxygen delivery function. Erythrocyte-
committed progenitors undergo an enormous expansion to fulfill the demand for 
2x1011 new erythrocytes each day (Dzierzak and Philipsen, 2013). In the steady-
state hematopoiesis, around 1% of erythrocytes are replaced every day. This 
process is governed by erythropoietin, a hormone produced in the kidneys, whose 
production is tightly regulated. Developmental studies identified two distinct types of 
erythrocytes – embryonic and adult ones. They develop at different anatomical sites 
from distinct types of hematopoietic progenitors.  	
1.3.1 Erythropoiesis during fetal and embryonic development and 
postnatal life 
 
Erythrocytes are formed in two waves, a primitive wave followed by the definitive 
wave. Primitive erythropoiesis occurs in the yolk sac. Erythroid cells are derived 
from mesodermal cells that migrate to the yolk sac and come in close contact with 
endodermal cells (Kinder et al., 1999; Lawson et al., 1991). In the yolk sac, they 
form blood islands that contain large and enucleated primitive erythrocytes around 
day E7.5 in the mouse and between day 16 and day 20 of gestation in humans 
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(Tavian and Peault, 2005). Primitive erythropoiesis is characterized by the 
expression of embryonic globins e, g, and z that form a variety of tetramers. Definitive 
erythropoiesis occurs first in the fetal liver. This event is marked by the switch to the 
fetal hemoglobin HbF, that is composed of a2g2 tetramers. Around the time of the 
birth, fetal hemoglobin expression is silenced, and erythropoiesis moves to the bone 
marrow and spleen. Adult hemoglobin composed of a2b2 (HbA1) or a2d2 (HbA2) 
tetramers becomes responsible for oxygen transport (Sankaran et al., 2010). 
Erythroid cells are derived from HSCs and follow a differentiation path towards 
mature erythrocytes through multiple stages of progenitors (Figure 3).  
Most immature erythroid progenitors are called burst forming units-erythroid (BFU-
E) and give rise to a multi-subunit colony containing up to a few thousands of 
hemoglobinized cells in the methylcellulose culture (Gregory and Eaves, 1977). 
Their growth is dependent on stem cell factor (SCF), IL-3, and EPO. BFU-E 
progenitors appear in the bone marrow and to the lesser extent also in the peripheral 
blood (Figure 7). Following stage are colony forming units-erythroid (CFU-E). They 
form small colonies consisting of 10-120 cells appearing after 2-3 days (mouse) and 
5-8 days (human) in the methylcellulose. They are dependent entirely on EPO as a 
growth factor and do not appear in the peripheral blood under the normal 
circumstances (Koury and Bondurant, 1990a). 
 
 
 
 
 
 
 
 
 
Figure 7. Scheme of erythroid differentiation illustrates progressive stages of erythroid progenitors towards 
the mature erythrocytes. Relative cell sizes and presumed or known morphologic appearances at various 
stages are shown. PU.1 and GATA are transcription factors determine the commitment of HSC towards the 
erythroid fate. Transcription factor KLF-1 determines whether MEP will differentiate towards the erythroid or 
megakaryocyte progenitor. CFU-E progenitors and proerythroblasts (Pro EB) are dependent on the EPO 
signaling. Stages of hemoglobin synthesis display relative accumulations of hemoglobin as increasing 
intensity of red in the cytoplasm. Abbreviations: HSC, hematopoietic stem cell; MEP, megakaryocyte-
erythroid progenitor; BFU-E, burst-forming unit, erythroid; CFU-E, colony-forming unit, erythroid; Pro EB, 
proerythroblast; Baso EB, basophilic erythroblast; Poly EB, polychromatophilic erythroblast; Ortho EB, 
orthochromatic erythroblast; RET, reticulocyte; RBC, red blood cell; EPOR, erythropoietin receptor. Adapted 
from (Koury and Haase, 2015).  
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CFU-E progenitors undergo a series of rapid cell divisions through different 
maturation steps: proerythroblast, basophilic erythroblast, polychromatophilic 
erythroblast and orthochromatic erythroblast (Dzierzak and Philipsen, 2013). This 
progressive erythroid precursor maturation is characterized by the decrease in cell 
size and accumulation of hemoglobin. Hemoglobin synthesis begins in the late 
basophilic erythroblast and continues through to the reticulocyte stage. At the 
terminal stage of erythrocyte differentiation, cells lose their ability to proliferate, 
perform nuclear condensation and expel the nucleus before they enter the 
circulation as reticulocytes. Reticulocyte maturation is a complex process 
characterized by 20% loss of plasma membrane surface area, reduction of cell 
volume and loss of cytoplasmic organelles (Johnstone, 1992; Ney, 2011). It takes 
reticulocytes around one week to fully mature into the bi-concave shaped 
erythrocytes with a lifespan of around 115 days (Franco, 2012). Senescent 
erythrocytes are phagocytosed by splenic, hepatic or bone marrow macrophages 
(Willekens et al., 2008). Erythroid differentiation takes place in the bone marrow in 
the structural unit called erythroblastic island (Chasis and Mohandas, 2008). 
Erythroblastic island is composed of a central macrophage, also called a nurse cell 
and erythroid cells at various stage of differentiation (Figure 8).   
 
 
 
\ 
 
Cell death signaling also plays an important role in erythroid differentiation. Up to 
60% of erythroblasts commit apoptosis in the mouse spleen under steady-state 
conditions (Liu et al., 2006). Signaling induced by erythropoietin prevents apoptosis 
of CFU-Es, proerythroblasts, and early basophilic erythroblasts (Koury and 
Bondurant, 1990b; Muta and Krantz, 1993; Wu et al., 1995). Individual erythroid 
progenitors have a significantly different sensitivity to erythropoietin that is 
Figure 8. An erythroblastic island. A) Immunohistology image of E13.5 mouse fetal liver shows a central 
macrophage stained with the F4/80 antibody in brown surrounded by erythroid cells at various stages of 
differentiation. B) Schematic drawing of an erythroblastic island. Reticulocytes detach from the macrophage 
before leaving the bone marrow and entering the circulation. Adapted from (Dzierzak and Philipsen, 2013).  
11 
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associated with varying expression of the CD95 (FAS) death receptor during the 
differentiation process. Upon binding of CD95L (FASL), a ligand of CD95 receptor, 
produced by the mature erythroblasts within the erythroblastic island (De Maria et 
al., 1999), progenitor cells activate caspase-3 dependent pro-apoptotic signaling 
pathways (Gregoli and Bondurant, 1999; Rubiolo et al., 2006). This negative 
feedback loop efficiently controls the rate of erythrocyte production (Kelley et al., 
1993).  
 
1.3.2 Transcriptional regulation of erythropoiesis 	
Multiple transcription factors are involved in the establishment of the erythroid 
lineage. GATA1 plays an essential role in the expression of erythroid-specific genes, 
as GATA1 deficiency causes the arrest at the proerythroblast stage (Fujiwara et al., 
1996; Pevny et al., 1995). Different functional domains of GATA1 are required for 
the activation of target genes in primitive and definitive stages of erythropoiesis, 
suggesting GATA1 is a part of different transcriptional complexes (Shimizu et al., 
2001).  
Another important transcription factor is KLF1, that is responsible for the terminal 
erythroid differentiation (Miller and Bieker, 1993). KLF1 expression is largely 
restricted to the erythroid cell lineage (Southwood et al., 1996). Homozygous 
deletion of KLF1 in mice causes fatal anemia in the developing fetus around day 
E14, due to the lack of b-globin expression, when embryos switch to the definitive 
erythropoiesis in the fetal liver (Nuez et al., 1995; Parkins et al., 1995). Importantly, 
the number of CFU-E cells in the KLF1 homozygous mutants is similar to their 
wildtype siblings, indicating that the KLF1 deficiency causes a very late erythroid 
defect (Nuez et al., 1995; Parkins et al., 1995). Moreover, KLF1-deficient erythroid 
progenitors have abnormal morphology and fail to expel the nuclei, indicating that 
b-globin is not the only target of KLF1. Indeed, genome-wide expression analysis of 
KLF1-deficient erythroid cells showed that KLF1 activates multiple erythroid-specific 
genes including fetal and adult globins (Basu et al., 2007; Hodge et al., 2006; 
Merryweather-Clarke et al., 2011). 
 
1.3.3 Erythropoietin (EPO) and erythropoietin receptor (EPOR) 	
A humoral “factor” that regulates erythropoiesis was first described by Carnot and 
Deflandre as a result of an experiment, in which increased red blood cell counts 
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were observed in normal rabbits after the infusion with the serum of anemic animals 
(Carnot and Deflandre, 1906). Later confirmed by Erslev (Erslev, 1953), these 
studies led to the hypothesis about circulating erythroid-stimulating hormone,  
termed erythropoietin (EPO). Organ ablation studies in rats (Jacobson et al., 1957) 
and man (Mirand et al., 1969; Nathan et al., 1964) further established kidney as the 
major site of EPO production. This led to the isolation of EPO protein from the urine 
of aplastic anemia patients (Miyake et al., 1977) and to the molecular cloning of the 
EPO gene (Jacobs et al., 1985; Lin et al., 1985).  
2901 base pairs long human EPO gene localizes to the chromosome 7q22.1, 
contains 5 exons and produces a 193-residue polypeptide with the molecular weight 
of 30.4 kDa. Heavy glycosylation that accounts for 40% of the molecular weight, 
slightly impedes its biological activity. However, it is critical for maintaining long half-
life in the serum, that reaches around 7-8 hours (Goldwasser et al., 1974). EPO 
binds with a high affinity (~100pM) to the cognate EPO receptor (EPOR) that is 
present in relatively small numbers (~1000 molecules/cell) on the surface of 
erythroid progenitors (Bunn, 2013).  
Human erythropoietin receptor encoded by 6 exons on chromosome 19p13.2 
produces a 508-amino acid polypeptide with a molecular weight of 55 kDa It is a 
member of the type I cytokine receptor family (Figure 5) and is present on the cell 
membrane as a homodimer, even in the absence of the ligand (Livnah et al., 1999). 
Binding of EPO causes the conformational change that brings its intracellular 
domains into the proximity (Figure 9). This leads to the initiation of JAK2-mediated 
intracellular signaling events (described in detail in chapter 1.2.1) and activation of 
several signaling axes JAK/STAT, PI3K/Akt, ERK/MAPK and PKC pathways 
(Richmond et al., 2005; Witthuhn et al., 1993; Youssoufian et al., 1993). 
Erythropoietin-EPOR complexes are subsequently degraded by endocytosis (Gross 
and Lodish, 2006).  
During embryonic development, erythropoietin production takes place in the liver, in 
hepatocytes surrounding the central vein (Koury et al., 1991) and Ito presinusoidal 
cells are (Maxwell et al., 1994). Around the birth, EPO synthesis gradually moves to 
the kidneys that become the primary site of the EPO in adult life. Although this switch 
is well documented in multiple species (Bondurant et al., 1991; Dame et al., 1998; 
Eckardt et al., 1992; Peschle et al., 1975; Zanjani et al., 1981), molecular 
mechanisms leading to this switch remain elusive. 
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Upon cleavage of the signal peptide in the endoplasmic reticulum and subsequent 
glycosylation in Golgi, a 166-aminoacid polypeptide is exported outside the cell.  
It has been suggested that the spatio-temporal expression of GATA transcription 
factors may play a role in this process (Weidemann and Johnson, 2009). GATA 
proteins belong to the family of zinc-finger DNA-binding proteins and play critical 
roles in cell growth and differentiation (Lentjes et al., 2016). The liver does not 
contribute to the plasma erythropoietin pool under physiological conditions in adults. 
In severe hypoxia, however, hepatocytes are capable of synthesizing EPO that 
accounts for the majority of systemic erythropoietin of non-renal origin (Fried, 1972; 
Fried et al., 1969; Mirand et al., 1969; 1968; Obara et al., 2008).  
The constant ratio between blood perfusion and oxygen consumption, together with 
low tissue pO2 and stable corticomedullary oxygen gradient, make kidney an ideal 
organ for sensing pO2 concentration (Wenger and Hoogewijs, 2010). Although 
several studies proposed that erythropoietin is produced by renal epithelial cells 
(Loya et al., 1994; Maxwell et al., 1990; Mujais et al., 1999), genetic models 
combined with immunohistochemistry and in situ hybridization identified peritubular 
interstitial cells on the medulla-cortex boundary as the physiological source of 
erythropoietin (Figure 10)  (Bachmann et al., 1993; Koury et al., 1988; 1989; 
Lacombe et al., 1988; Obara et al., 2008). Several studies showed that the number 
of renal EPO-producing cells (REPs) increases proportionally to the degree of 
hypoxia, and therefore the number of REPs determines the renal contribution to the 
plasma EPO levels (Obara et al., 2008; Souma et al., 2013; Yamazaki et al., 2013). 
Figure 9. EPO-mediated signaling. EPO receptor (EPOR) is present on the cell surface even in the absence 
of the ligand. Binding of EPO causes a conformational change that brings intracellular domains of the receptor 
into close proximity. This causes the transphosphorylation of associated JAK2 kinase and initiates the signal 
transduction cascade. Adapted from (Bunn, 2013).  
 
 
 
 
 
An erythroblastic island. A) Immunohistology image of E13.5 mouse metal liver shows a central macrophage 
stained with the F4/80 antibody in brown surrounded by erythroid cells at various stages of differentiation. B) 
Schematic drawing of an erythroblastic island. Reticulocytes detach from the macrophage before leaving the 
bone marrow and entering the circulation. Adapted from (Dzierzak and Philipsen, 2013)1 
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In addition to the kidney and liver, EPO expression was also detected in other 
tissues, such as neurons and glial cells, bone marrow cells, osteoblasts, spleen, hair 
follicles, lung tissue, cardiomyocytes, and reproductive organs (Bernaudin et al., 
2000; Bodo et al., 2007; Dame et al., 1998; Fandrey and Bunn, 1993; Marti et al., 
1996; Miro-Murillo et al., 2011; Rankin et al., 2012; Yasuda et al., 1998). These 
organs are thought not to contribute significantly to the systemic erythropoietin pool, 
but rather to exert local, non-hematopoietic actions, such as angiogenesis, brain 
development, and wound healing (Arcasoy, 2008; Jelkmann, 2007).  
 
1.3.4 Erythropoietin regulation 	
Erythropoiesis is stimulated by hypoxia that activates hypoxia-inducible factors (HIF). 
HIFs are the master regulators of cellular response to the hypoxic stimulus. In 
addition to the stimulation of renal end hepatic erythropoietin production, they also 
promote the uptake and utilization of iron and modify the bone marrow 
microenvironment to support the maturation and proliferation of erythroblasts. The 
discovery of human hepatoma cell lines, Hep3B, and HepG2 that up-regulate EPO 
expression in a hypoxia-dependent manner greatly facilitated the initial studies of 
EPO gene regulation (Goldberg et al., 1987). 
The EPO gene promoter contains a GATA-binding motif with the core sequence 5’-
AGATAACA-3’, that facilitates the binding of GATA proteins. It was reported that 
human GATA-1, GATA-2, and GATA-3 are able to bind to the core EPO promoter 
sequence, inhibit the formation of pre-initiation complexes and thereby reduce the 
expression levels of EPO mRNA in Hep3B cells. (Aird et al., 1994; Imagawa et al., 
1997; 2002). In addition, GATA-2 and GATA-3 were shown to constitutively repress 
Figure 10. Renal EPO-producing cells (REPs). Panel A illustrates a schematic picture of proximal tubules (PT) 
formed by epithelial cells. Peritubular interstitial cells that produce EPO are depicted in green. Panel B shows 
that GFP-labeled REPs are located on the medulla-cortex boundary. Panel C displays a close-up look on the 
proximal tubule region with peritubular interstitial cells labeled in green. Panel A is adapted from (Noguchi, 2008) 
and panels B and C from (Pan et al., 2011). 
 
 
 
 
 
An erythroblastic island. A) Immunohistology image of E13.5 mouse metal liver shows a central macrophage 
stained with the F4/80 antibody in brown surrounded by erythroi  cells at vario s stages of differentiation. B)
Schematic drawing of an erythroblastic island. Reticulocytes detach from the macrophage before leaving the 
bone marrow and entering the circulation. Adapted from (Dzierzak and Philipsen, 2013)1 
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EPO in renal tubular cells in the kidney in vivo (Obara et al., 2008). Thus, it has been 
suggested that the GATA box acts as a negative regulatory element that represses 
the transcription during normoxia. In contrast, GATA-4 was proposed to have a 
positive effect on EPO expression in Hep3B cells, since knockdown of GATA-4 
negatively influenced EPO mRNA levels (Dame et al., 2004). In hypoxia, GATA 
binding markedly decreases, which allows for a significant increase in EPO gene 
expression. Since EPO promoter has a weak activity, an enhancer element is 
necessary to upregulate EPO expression under hypoxic conditions. 
Enhancer elements differ between kidney and liver. In the kidney, an essential 
regulatory element for renal EPO expression is located between -14kb and -6kb 
upstream of the EPO gene (Semenza et al., 1990). A recent study identified HIF 
binding site 9248 base pairs upstream of EPO transcriptional start site and provided 
in vitro evidence that it acts as a HIF-2 dependent distal hypoxia response element 
(HRE)  (Storti et al., 2014). Since 180 kilobase BAC transgene is required to 
recapitulate endogenous EPO expression in the transgenic mouse model (Obara et 
al., 2008; Yamazaki et al., 2013), there are probably multiple upstream regulatory 
elements existing.  
In the liver, HRE is located in the 3’-region downstream of the EPO gene and 
contains classical hypoxia enhancer that is essential for the hypoxic induction of 
EPO in the hepatocytes (Blanchard et al., 1992; Semenza et al., 1991; Suzuki et al., 
2011). HIF transcription factors bind to the consensus sequence 5’-TACGTGCT-3’  
within this regulatory element, cooperate with hepatocyte nuclear factor (HNF-4) 
and the transcriptional co-activator p300 to initiate the transcription of hypoxia-
response genes (Semenza et al., 1991).  
HIF transcription factors are heterodimeric proteins consisting of an oxygen-
sensitive a-subunit and constitutively expressed b-subunit, also called aryl 
hydrocarbon receptor nuclear translocator (ARNT). To date, 3 distinct a-subunits 
were identified in man and named HIF-1a (Wang et al., 1995), HIF-2a (Tian et al., 
1997), and HIF-3a (Gu et al., 1998). HIF-1a is ubiquitously expressed, whereas HIF-
2a has tissue-restricted expression. Most of the studies have focused on HIF-1 and 
HIF-2 that are mainly involved in the hypoxia-stimulated cellular response. HIF-1a 
is ubiquitously expressed, whereas HIF-2a has tissue-restricted expression. 
Although HIF-1 and HIF-2 regulate expression of many genes (Schödel et al., 2011), 
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HIF-2 is the isoform responsible for the erythropoietin synthesis and iron metabolism 
(Gruber et al., 2007; Kapitsinou et al., 2010; Mastrogiannaki et al., 2009; Rankin et 
al., 2007; Scortegagna et al., 2005). 
HIF-a subunits are being constitutively synthesized. Therefore, control of the 
degradation rate is a key step in the erythropoiesis regulation. HIF-a is remarkably 
unstable under normal oxygen levels (Huang et al., 1996). Oxygen-dependent HIF-
a  degradation is initiated by prolyl-4-hydroxylase domain (PHD) oxygenases; PHD1, 
PHD2, and PHD3 (also known as EGLN2, EGLN1, and EGLN3). PHD2 is the main 
oxygenase responsible for the degradation of HIF proteins under the normoxia. 
These enzymes use molecular oxygen to hydroxylate HIFa subunits at specific 
proline residues, Pro402, and Pro564 in human HIF-1α; Pro405, and Pro531 in 
human HIF-2α (Bruick and McKnight, 2001; Epstein et al., 2001; Hon et al., 2002; 
Ivan et al., 2001; Jaakkola et al., 2001; Yu et al., 2001). β-domain of von Hippel-
Lindau (VHL) protein binds to the proline-hydroxylated HIF-a that is subsequently 
recognized by VHL-E3-ubiquitin ligase complex. This complex polyubiquitinates 
HIF-α and targets it for proteasomal degradation. In hypoxic conditions, 
hydroxylation of HIFa subunits is inhibited, HIF heterodimers translocate to the 
nucleus and activate the transcription of hypoxia-response genes (Figure 11). Lack 
of HIF expression leads to anemia (Gruber et al., 2007; Kapitsinou et al., 2010; 
Scortegagna et al., 2003), whereas impaired regulation of its activity results in 
erythrocytosis (Percy et al., 2008; Rankin et al., 2007).  
In addition to the regulation of hypoxia-stimulated erythropoietin production, HIF-2 
also plays a critical role in the regulation of iron uptake. It upregulates transcription 
of a divalent metal transporter (DMT1) and duodenal cytochrome b reductase 1 
(DCYTB) genes (Shah et al., 2009). DCYTB reduces ferric iron (Fe3+) to its ferrous 
form (Fe2+) and DMT1 transports the iron from the gut lumen to the cytoplasm of the 
cells. HIF proteins also regulate the expression of transferrin (TF), which transports 
iron in the plasma (Rolfs et al., 1997), transferrin receptor (TFRC) involved in the 
iron uptake by the cells (Lok and Ponka, 1999), heme-oxygenase-1 (HO-1) that is 
responsible for the iron recycling from phagocytosed erythrocytes (Lee et al., 1997), 
and ferroportin (FPN), the only known cellular iron exporter (Taylor et al., 2011).  
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1.3.5 Dysregulated EPO production and associated clinical syndromes 
 
When renal EPO-producing cells (REPs) lose the ability to produce erythropoietin, 
it leads to the renal anemia. This is mostly caused by the trans differentiation of 
REPs into myofibroblasts (Falke et al., 2015; Humphreys et al., 2010; Lin et al., 
2008). Patients with renal failure have much lower serum EPO levels when 
compared to the anemic patients with intact kidney function (Erslev, 1991). 
Treatment with erythropoiesis-stimulating agents (ESA) such as darbepoetin a or 
epoetin b leads to the improvements of the renal anemia. Although this therapy is 
very effective in the majority of patients, some patients do not respond to the 
treatment. Moreover, varying levels of hemoglobin due to the stimulating agents 
were associated with increased cardiovascular risk (Besarab et al., 1998; Boudville 
et al., 2009; Drueke et al., 2006; Pfeffer et al., 2009; Singh et al., 2006). Hence, 
pharmacological stabilization of HIF proteins may offer an alternative therapeutic 
Figure 11. Hypoxic induction of erythropoietin production is regulated by the balance of HIF and PHD proteins.  
In normoxic conditions, i.e. in the presence of oxygen, HIF-α is hydroxylated at specific proline residues by 
prolyl-4-hydroxylase domain (PHD) oxygenases. Hydroxylation causes the binding of the β-domain of VHL that 
functions as a substrate recognition component of the VHL-E3-ubiquitin ligase complex. This complex 
polyubiquitinates HIF-α and targets it for proteasomal degradation (upper panel). Under hypoxic conditions, 
HIF-α degradation is inhibited, because PHD enzymes need molecular oxygen to hydroxylate HIF-α proteins. 
HIF-α translocates to the nucleus, where it forms a heterodimer with HIF-ß subunit (ARNT) and binds hypoxia 
regulatory elements in the proximity of the EPO gene. Liver-inducibility element located downstream of the EPO 
gene mediates hypoxic induction of EPO in the liver. Hypoxic induction of renal EPO requires the kidney 
inducibility element located upstream of the EPO gene (lower panel.) Boxes depict EPO exons. EPO coding 
sequences and non-translated sequences are depicted in red and blue, respectively. The distance from the 
EPO transcription start site is indicated in kilobases. Abbreviations: 2OG, 2-oxoglutarate; ARNT, aryl 
hydrocarbon receptor nuclear translocator: HNF-4, hepatocyte nuclear factor 4; PHD, prolyl-4-hydroxylase 
domain. Adapted from (Koury and Haase, 2015).  
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approach with several advantages, such as keeping EPO serum levels within the 
physiological range, enhanced iron absorption, and the possibility for oral dosing. 
This stimulated the development of PHD inhibitors (PHIs) (Barrett et al., 2011; 
Bernhardt et al., 2010; Boettcher et al., 2018; Brigandi et al.; Provenzano et al., 
2016). Unlike in the kidney EPCs, where inactivation of PHD2 alone is sufficient to 
induce erythropoietin expression, all three PHD isoforms have to be inactivated to 
re-establish EPO expression in the liver (Minamishima and Kaelin, 2010).  
Also, a genetic mutation in the EPO gene resulting in a non-functional protein was 
reported to cause severe anemia (Kim et al., 2017). Conversely, genetic mutations 
in VHL (Ang et al., 2002), PHD2 (EGLN1) (Ladroue et al., 2008), HIF2A (EPAS2) 
(Percy et al., 2008), HGB (Charache et al., 1966), BPGM (Hoyer et al., 2004), and 
EPO (Zmajkovic et al., 2018) cause excessive production of erythropoietin, leading 
to the increased red blood cell count and a disease called erythrocytosis, that is 
discussed in more detail in chapter 1.5.1.  
 
1.4 Thrombopoiesis 	
Platelets, or thrombocytes, looking like small oval discs with an average size of 
2.5x5.0 μm, are essential components of hemostasis and thrombosis. Every day, 
around 1011 platelets are produced by a human body to replace platelets at the end 
of their 10-day life cycle (Kaushansky, 2005).  Platelets are produced from platelet 
progenitors - megakaryocytes, in a process called platelet biogenesis or 
megakaryocytopoiesis.  	
1.4.1 Platelet biogenesis 	
Burst-colony forming unit megakaryocyte (BFU-MK) cells are the most primitive 
megakaryocyte-committed progenitors with highest proliferative capacity, that form 
colonies of more than 50 cells in methylcellulose (Briddell et al., 1989; Long et al., 
1985). Next stage is colony-forming unit megakaryocyte progenitor (CFU-MK), with 
a lower proliferation capacity, that gives rise to colonies of ~ 5 to 50 cells (McLeod 
et al., 1976) (Vainchenker et al., 1979). CFU-MK progresses through the 
megakaryoblast stage towards the mature megakaryocyte (Figure 12).   
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Megakaryocytes (MK) replicate their DNA without cytokinesis in a process called 
endomitosis. During endomitosis, multipolar mitotic spindles with the number of 
poles corresponding to the ploidy level are being assembled, but they fail to separate. 
This generates a polyploid, multilobed nucleus with up to 128N DNA in man and up 
to 256N in mouse (Nagata et al., 1997; Vitrat et al., 1998). Besides DNA duplication, 
also cytoplasmic content undergoes reorganization, and interconnected network of 
cisternae and tubules called the demarcation membrane system (DMS) is formed 
(Radley and Haller, 1982). The proplatelet formation is initiated, when 
megakaryocyte starts to form pseudopodia that continue to elongate until they 
become proplatelets (Choi et al., 1995; Cramer et al., 1997). Megakaryocytes 
continue to generate proplatelets until the entire megakaryocyte cytoplasm is 
transformed into a network of interconnected proplatelets (Italiano et al., 1999). 
Platelets are formed and released from the swellings at the proplatelet ends (Junt 
et al., 2007). It was estimated that a single megakaryocyte releases ~ 2000-3000 
platelets (Long, 1998).  
In addition to thrombopoietin (TPO), a major platelet-stimulating factor, also other 
growth factors were found to be implicated in platelet biogenesis: IL-3, IL-6 and SCF 
for early progenitor stage; TGF-b (transforming growth factor b) and IFN-
a (interferon a) for megakaryocyte maturation; and BMP4 (bone morphogenic 
protein 4) and FGF4 (fibroblast growth factor 4) for the platelet release.  
Figure 12. Platelet biogenesis. Different progressive stages of platelet progenitors towards mature 
thrombocytes are shown. Abbreviations: HSC, hematopoietic stem cell; CMP, common myeloid progenitor; 
BFU-E/MK, burst-colony forming unit-erythroid/megakaryocyte; BFU-MK, burst-colony forming unit 
megakaryocyte, CFU-MK, colony-forming unit megakaryocyte; MK, megakaryocyte. Adapted from (Chen et 
al., 2013).  
 
 
 
 
 
 
An erythroblastic island. A) Immunohistology image of E13.5 mouse metal liver shows a central macrophage 
stained with the F4/80 antibody in brown surrounded by erythroid cells at various stages of differentiation. B) 
Schematic drawing of an erythroblastic island. Reticulocytes detach from the macrophage before leaving the 
bone marrow and entering the circulation. Adapted from (Dzierzak and Philipsen, 2013)1 
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1.4.2 Transcriptional regulation of thrombopoiesis 	
Several transcription factors are involved in the establishment of megakaryocytic 
lineage. In the early commitment, GATA-1 is essential for lineage commitment 
towards megakaryocyte-erythrocyte bipotential progenitor, as well as for 
megakaryocyte development and proliferation (Crispino, 2005). Selective GATA-1 
knock-out in megakaryocytic lineage results in thrombocytopenia and higher 
numbers of immature megakaryocytes with decreased polyploidization (Shivdasani 
et al., 1997). GATA-1 recruits diverse co-regulators to chromatin, that mediate 
transcriptional activation or repression (Pope and Bresnick, 2010). One of the 
examples is Friend of GATA-1 (FOG-1), that binds to GATA-1 and together they 
synergistically activate transcription from the hematopoietic-specific regulatory 
region (Tsang et al., 1997). GATA-1 loss-of-function leads to the severe congenital 
X-linked thrombocytopenia (Nichols et al., 2000) and megakaryoblastic leukemia 
(Wechsler et al., 2002). 
Another transcription factor essential for megakaryopoiesis is Fli-1], regulating late 
stages of megakaryocytic differentiation (Bastian et al., 1999). Mice null for Fli-1 die 
during the embryonic development due to the defects in vascular development and 
megakaryopoiesis Fli-1 co-operates with FOG-1 and GATA-1 to activate the 
transcription of genes involved in late megakaryopoiesis, such as GPIX or PF4 
(Wang et al., 2002).  
RUNX-1 (AML-1) binds to the N-terminal part of GATA-1 and contributes to the 
megakaryocyte lineage commitment (Elagib et al., 2003). Loss-of-function 
mutations in RUNX1 lead to the familial thrombocytopenia and can progress to AML 
(Song et al., 1999). The NF-E2 transcription factor, a heterodimeric leucine zipper, 
was shown to control terminal megakaryocyte maturation, proplatelet formation and 
platelet release (Deveaux et al., 1997; Lecine et al., 2000). NF-E2 knock-out mice 
display arrest of megakaryocyte maturation and severe thrombocytopenia, resulting 
in embryonic lethality and demonstrating the essential role of NF-E2 in platelet 
biogenesis (Lecine et al., 1998; Shivdasani et al., 1995). 	
1.4.3 Thrombopoietin (TPO) and thrombopoietin receptor (c-MPL) 
 
Thrombopoietin, also known as a c-Mpl ligand, is the primary cytokine regulating the 
proliferation of megakaryocytes (Kaushansky et al., 1995). It is produced by 
hepatocytes in the liver, and to a lesser degree also in the kidney, bone marrow, 
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and spleen (Sungaran et al., 1997). Besides its role in megakaryopoiesis, it also has 
a well-documented role in the survival and proliferation of HSCs (Decker et al., 2018; 
Kaushansky, 2006; Qian et al., 2007; Yoshihara et al., 2007).  
The concept of thrombopoietin was first used in 1958 to describe yet unidentified 
hormone responsible for platelet production (Kelemen et al., 1958). THPO gene was 
not identified until its receptor, c-MPL was discovered in 1992 (Skoda et al., 1993; 
Vigon et al., 1992), by searching for the human and mouse homologs of a viral 
oncogene v-MPL (Souyri et al., 1990). This led to the successful cloning of the 
THPO gene (Bartley et al., 1994; de Sauvage et al., 1994; Kaushansky et al., 1994; 
Lok et al., 1994). The 6.1 kilobases long human THPO is located on chromosome 
3q26.3-3q27 and contains 7 exons, of which first 3 are non-coding and have a 
regulatory function (Foster et al., 1994). Translation of THPO mRNA produces a 
353-residue polypeptide that upon cleavage of the signal peptide has a length of 
332 amino acids and molecular weight of 37.1 kDa. In a long, untranslated 5’-end, 
7 upstream open reading frames reside. They are able to initiate the translation and 
thereby decrease the availability of ribosomes for physiological start codon, AUG8 
(Ghilardi et al., 1998). uORF7 extends beyond the AUG8 and is, therefore, the 
strongest negative regulator of the translation. 
Until recently, TPO production was sought to be constitutive (Stoffel et al., 1995), 
with TPO plasma levels regulated by the uptake of the TPO by megakaryocytes and 
platelets expressing c-MPL on their surface (Broudy et al., 1997; Fielder et al., 1996; 
1997). Hence, TPO concentration in serum would be inversely correlated to the 
megakaryocyte mass in the bone marrow and platelet counts (Kuter and Rosenberg, 
1995; Shinjo et al., 1998). Nevertheless, serum TPO levels are higher than expected 
in patients with essential thrombocythemia (Griesshammer et al., 1998) and lower 
than expected in patients with immune thrombocytopenia (Ichikawa et al., 1996; 
Kosugi et al., 1996). Besides, megakaryocyte-restricted deletion of c-MPL and JAK2 
leads to profound megakaryocytosis and thrombocytosis, suggesting that TPO 
signaling in megakaryocytes is not required for the platelet production (Meyer et al., 
2014; Ng et al., 2014). Intriguingly, TPO serum levels in these murine models were 
in the normal range (Meyer et al., 2014; Ng et al., 2014). Also, IL-6 was shown to 
increase hepatic THPO mRNA expression, as a result of the inflammatory state 
(Burmester et al., 2005; Kaser et al., 2001; Wolber et al., 2001). In the steady-state 
conditions, clearance of asialylated senile platelets through the Ashwell-Morell 
receptor (AMR) was proposed to stimulate THPO mRNA expression via 
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JAK2/STAT3 pathway (Grozovsky et al., 2015). Platelets cleared independently of 
the AMR do not increase hepatic TPO expression.  Furthermore, a recent report 
attributed a role of glycoprotein receptor GPIba in hepatic TPO production, 
indicating that GPIba glycans on the platelets are recognized by AMR to initiate TPO 
production (Xu et al., 2018). All this evidence implies that TPO serum levels are 
regulated in a complex manner, and further investigation is required to fully 
understand the underlying mechanism.  
The gene encoding for the TPO receptor, c-MPL, comprises 12 exons located on 
chromosome 1p34 in man (Mignotte et al., 1994). TPO receptor is a member of the 
type I cytokine receptor family (Figure 5), and binding of TPO ligand leads to the 
initiation of JAK2-mediated intracellular signaling events (described in detail in 
chapter 1.2.1). Knock-out of either THPO or c-MPL leads to more than 80% 
reduction in platelet counts and profound thrombocytopenia in mouse models, 
stressing the critical role of these 2 components in thrombopoiesis (de Sauvage, 
1996; Gurney et al., 1994).  
Multiple inactivating mutations in c-MPL leading to amegakaryocytic 
thrombocytopenia, a disease that requires hematopoietic stem cell transplantation, 
were reported (Ballmaier et al., 2001; Ihara et al., 1999; van den Oudenrijn et al., 
2000). Recently, also a mutation in the THPO gene was reported to cause 
amegakaryocytic thrombocytopenia (Pecci et al., 2018). Conversely, activating 
mutations in both thrombopoietin receptor and ligand lead to TPO-independent 
signaling and cause hereditary thrombocytosis (Cazzola and Skoda, 2000; Ding, 
2004) or essential thrombocytosis (Pardanani et al., 2006; Pikman et al., 2006).  
For patients suffering from thrombocytopenia, recombinant human TPO was 
synthesized following the success of rhEPO in treating anemic patients. Despite the 
initial rise in platelet counts, some of the clinical study subjects developed 
paradoxical thrombocytopenia, owing to the production of neutralizing 
autoantibodies (Li et al., 2001). Hence, romiplostim (Bussel et al., 2006; Cwirla et 
al., 1997) and eltrombopag (Erickson-Miller et al., 2004; Saleh et al., 2013) TPO 
receptor agonists have been developed as a substitution therapy.  
 
1.5 Hereditary myeloproliferative disorders 	
Myeloproliferative disorders (MPD) also called myeloproliferative neoplasms (MPN), 
are a heterogeneous group of clonal blood disorders, characterized by the increased 
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numbers of mature blood cells. A high level of red blood cells defines polycythemia 
vera (PV), high level of platelets essential thrombocytosis (ET), and presence of 
fiber and blasts in bone marrow describes primary myelofibrosis (PMF). These three 
diseases are distinguished based on blood counts, bone marrow biopsies and the 
presence of somatic driver mutations in JAK2  (Baxter et al., 2005; James et al., 
2005; Kralovics et al., 2005; Levine et al., 2005), CALR (Klampfl et al., 2013; 
Nangalia et al., 2013), and c-MPL (Pikman et al., 2006).  
In addition to the spontaneous acquired somatic forms of MPN, there are also 
familiar forms of MPN existing, usually having clinical symptoms indistinguishable 
from the somatic forms. Hereditary MPNs are caused by the germline mutations 
transmitted through Mendelian inheritance within the pedigree. Two classes of 
hereditary MPNs exist: 
 
1. Inherited disorders with the Mendelian transmission, characterized by high to 
complete penetrance and polyclonal hematopoiesis.  
 
2. Hereditary predisposition to true MPN, characterized by low penetrance, clonal 
hematopoiesis, and co-occurrence of somatic mutations. 	
1.5.1 Hereditary erythrocytosis 	
Erythrocytosis is diagnosed, when red cell mass is greater than 125% of that 
predicted for sex and body mass (Keohane et al., 2013). Since determining red cell 
body mass is a highly specialized test, clinicians use indirect parameters such as 
hemoglobin and hematocrit values to diagnose erythrocytosis. Based on the most 
recent WHO guidelines, acquired erythrocytosis (polycythemia vera) is 
characterized by hemoglobin above 16.5 g/dL in men and 16.0 g/dL in women or 
hematocrit above 49% in men and 48% in women (Arber et al., 2016).  
Primary erythrocytosis is caused by an intrinsic defect in erythroid progenitors or 
stem cells and is accompanied by low serum EPO levels. Inherited forms of primary 
erythrocytosis are caused by mutations in the EPOR (La Chapelle et al., 1993; Sokol 
et al., 1995), SH2B3 (LNK) (Maslah et al., 2017; Rumi et al., 2016), and JAK2 
(Kapralova et al., 2016).  
Secondary erythrocytosis is characterized by elevated EPO serum levels, and is 
mainly caused by the mutations in genes involved in oxygen sensing pathway, such 
as VHL (Ang et al., 2002; Cario et al., 2005), PHD2 (EGLN1) (Ladroue et al., 2008) 
and HIF2A (EPAS1) (Percy et al., 2008). Also, mutations in genes affecting the 
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hemoglobin HGB (Charache et al., 1966), and BPGM (Hoyer et al., 2004) were 
reported to cause erythrocytosis. Most recently we reported a germline mutation in 
the EPO gene to cause secondary erythrocytosis (Zmajkovic et al., 2018). The 
prevalence of primary erythrocytosis (PV) is estimated to 44-57 cases per 100 000 
(Mehta et al., 2014), whereas the prevalence of secondary erythrocytosis is difficult 
to estimate, but is thought to be < 1: 100 000 (Hussein et al., 2012).  
Therapeutic approaches for treating erythrocytosis include phlebotomy (venesectio) 
and low dose aspirin to prevent thrombosis and resulting myocardial infarction and 
stroke (Landolfi et al., 2004). In addition, several cytoreductive treatments, such as 
busulfan and hydroxyurea are used, especially for polycythemia vera patients with 
somatic JAK2 mutations.  
 
1.5.2 Hereditary thrombocytosis 	
Thrombocytosis, or sometimes called also thrombocythemia is classified by the 
increase in the number of thrombocytes above 450x109/L for the period over 6 
months (Hussein et al., 2014), (Arber et al., 2016). Based on the platelet counts, 
thrombocytosis may be classified as mild (450-700 x109/L), moderate (700-900 
x109/L) or severe (>900 x109/L) (Teofili and Larocca, 2011).  
Familial thrombocytosis can be classified as primary when the defect is intrinsic to 
the megakaryocyte progenitors in the bone marrow. Mutations in the genes 
involved in the TPO signaling pathway, c-MPL (Ding, 2004; El-Harith et al., 2009; 
Liu et al., 2009; Moliterno et al., 2004; Teofili et al., 2010), and JAK2 (Bellanne-
Chantelot et al., 2006; Mead et al., 2012) lead to the TPO-independent signaling. 
Primary thrombocytosis is therefore accompanied by the low TPO serum levels.  
Secondary thrombocytosis is caused by the mutations in the THPO gene and is 
characterized by high TPO serum levels.  So far, three distinct mutations in the 
THPO gene were reported as a cause of hereditary thrombocythemia (Ghilardi and 
Skoda, 1999; Ghilardi et al., 1999; Graziano et al., 2009; Kikuchi et al., 1995; 
Kondo et al., 1998; Liu et al., 2008; Schlemper et al., 1994; Stockklausner et al., 
2012; Wiestner et al., 1998; Zhang et al., 2011). Mutations in other TPO-signaling 
associated factors, such as SH2B3, have not yet been reported. Prevalence of 
familial thrombocytosis is estimated below 1:100 000 (Teofili and Larocca, 2011). 
Therapy is based on low aspirin dosing to reduce thromboembolic risk.  
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2.1 A Gain-of-Function Mutation in EPO in Familial 
Erythrocytosis  	
 
A Gain-Of-Function Mutation in EPO in Familial Erythrocytosis. 
Zmajkovic J, Lundberg P, Nienhold R, Torgersen ML, Sundan A, Waage 
A, Skoda RC. N Engl J Med. 378:924-930 (2018). 
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Summ a r y
Familial erythrocytosis with elevated erythropoietin levels is frequently caused by 
mutations in genes that regulate oxygen-dependent transcription of the gene en-
coding erythropoietin (EPO). We identified a mutation in EPO that cosegregated 
with disease with a logarithm of the odds (LOD) score of 3.3 in a family with 
autosomal dominant erythrocytosis. This mutation, a single-nucleotide deletion 
(c.32delG), introduces a frameshift in exon 2 that interrupts translation of the 
main EPO messenger RNA (mRNA) transcript but initiates excess production of 
erythropoietin from what is normally a noncoding EPO mRNA transcribed from 
an alternative promoter located in intron 1. (Funded by the Gebert Rüf Foundation 
and others.)
Inherited forms of primary erythrocytosis with low serum levels of erythropoietin are caused by mutations in the erythropoietin-receptor gene (EPOR),1,2 SH2B3 (LNK),3,4 or JAK2.5 Inherited forms of secondary erythrocytosis 
with elevated erythropoietin levels are mainly caused by mutations in genes 
involved in oxygen-sensing pathways, such as VHL,6 PHD2 (EGLN1),7 and HIF2A 
(EPAS1),8 or by mutations in HGB9 or BPGM.10 Variants in candidate genes (e.g., 
EGLN2, EPO, HIF3A, and OS9) have been described,11 but their functional relevance 
has not been determined. Here, we describe a gain-of-function variant in EPO in 
an extended kindred with familial erythrocytosis, including 10 affected family 
members in four generations.
Me thods
Study Family
Part of the pedigree — including the index patient, in whom erythrocytosis was 
diagnosed in 1969 (WG02), and three affected family members (WG01, WG08, 
and WG11) — has been described previously.12 The study was approved by the 
Regional Committee for Medical and Health Research Ethics Central, Norway, and 
by Ethikkommission Beider Basel, Switzerland. All participating family members 
provided written informed consent to participate in the study.
Genetic and Molecular Analyses
Linkage analysis, microsatellite mapping, gene editing with the use of CRISPR 
(clustered regularly interspaced short palindromic repeats), cell-culture assays, 5′ 
RACE (rapid amplification of complementary DNA ends), and assessment of eryth-
ropoietin levels were performed as described in the Supplementary Appendix, 
available with the full text of this article at NEJM.org.
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R esult s
Clinical Findings and Laboratory Analysis
The pedigree of the Norwegian family with auto-
somal dominant erythrocytosis is shown in Fig-
ure 1A. The affected family members typically 
presented with symptoms of headache and dizzi-
ness that rapidly disappeared after initiation of 
phlebotomy.12 No incidents of venous or arterial 
thrombosis had occurred in a family member 
younger than 70 years of age in this pedigree.
The affected family members had hemoglobin 
levels above 180 g per liter in men or 160 g per 
liter in women, with the exception of one male 
family member (WG05), whose hemoglobin level 
was in the upper normal range, at 167 g per liter. 
One child (WG20) had a hemoglobin level of 190 g 
per liter shortly after birth; we do not have data 
obtained during infancy for the other members 
of the family. Additional laboratory data are pro-
vided in Table S1 in the Supplementary Appen-
dix. Erythropoietin concentrations in serum were 
elevated in most of the affected family members. 
When plotted against the linear regression calcu-
lated from hemoglobin and serum erythropoie-
tin levels of healthy persons,13 the erythropoietin 
level was found to be elevated in relation to the 
hemoglobin level in each affected family mem-
ber (Fig. 1B).
Genomewide Linkage Analysis 
and DNA Sequencing
Sequence analysis of genes that are known to be 
involved in erythrocytosis yielded negative results. 
Therefore, we performed genomewide linkage 
analysis and found a cosegregating region on 
chromosome 7q22.1 with a LOD score of 3.3 
(Fig. 1C, and Fig. S1 in the Supplementary Ap-
pendix). Targeted sequencing of all 215 genes 
within the cosegregating region (Table S2 in the 
Supplementary Appendix) revealed a heterozy-
gous single-base deletion in exon 2 of EPO (chro-
mosome 7: 100,319,199 GG→G) as the only 
candidate gene mutation (Fig. 1D). This c.32delG 
mutation (referred to in this report as ΔG) was 
present in all affected family members (Fig. 1A) 
and was absent from 138,632 exome and whole-
genome sequences reported in the Genome Ag-
gregation Database (gnomAD).14 Since erythro-
poietin is the primary regulator of erythropoiesis, 
the EPO ΔG deletion was an excellent candidate 
for the disease-causing mutation. The deletion 
creates a frameshift that truncates the erythro-
poietin signal peptide and generates a novel pep-
tide, terminating after an additional 51 amino 
acids (Fig. 1E), which would predict a loss of 
erythropoietin function and is at odds with the 
erythrocytosis phenotype.
Functional Characterization 
of the Mutated EPO
To determine whether alternative transcripts of 
EPO played a role in the phenotype of these pa-
tients, we used CRISPR to introduce the ΔG 
mutation into EPO. Since we had no access to 
kidney or liver tissues from the patients and 
were unable to detect EPO mRNA in erythroid 
colonies grown in vitro from a patient’s periph-
eral blood,15,16 we introduced the mutation into 
EPO in Hep3B cells, a human hepatoma cell line 
that expresses EPO.17 CRISPR-mediated genome 
editing (Fig. S2A in the Supplementary Appen-
dix) yielded multiple Hep3B single-cell clones 
that carried the ΔG mutation in the homozygous 
state (Fig. 2A, and Fig. S2B in the Supplemen-
tary Appendix).
We selected two Hep3B single-cell derived 
clones (ΔG1 and ΔG4) that were homozygous for 
the EPO ΔG mutation and assayed erythropoietin 
in the supernatants of these clonal cell lines 
grown in normoxic conditions; the supernatants 
contained 8 to 10 times as much erythropoietin 
as the supernatants of parental Hep3B cells or 
Hep3B cells in which CRISPR failed to modify 
EPO (Fig. 2B). These supernatants were capable 
of stimulating the growth of an erythropoietin-
dependent cell line (BaF3-EpoR), which suggested 
that the secreted erythropoietin was biologically 
active (Fig. 2C). The same conclusions were 
reached with Hep3B cells grown in hypoxic con-
ditions (Fig. S3 in the Supplementary Appendix). 
We therefore concluded that the ΔG deletion is, 
in fact, a gain-of-function mutation.
Study of EPO mRNA Transcripts
To understand how an ostensibly loss-of-function 
variant of EPO produces erythropoietin, we 
searched for alternative EPO mRNAs. In addition 
to the expected transcripts originating from the 
physiologic promoter (P1) upstream of exon 1, 
we discovered two alternative EPO mRNA tran-
scripts that originate from an alternative pro-
moter (P2) in intron 1 (Fig. 2D, and Fig. S4A in 
the Supplementary Appendix). The shorter tran-
script results from a splicing event that removes 
189 nucleotides from the longer intron 1 tran-
The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITY OF BASEL on March 10, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 378;10 nejm.org March 8, 2018926
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
script. We detected these two transcripts in pa-
rental Hep3B cells as well as in the ΔG clones; 
the longer P2 transcript was more abundant in 
the ΔG1 and ΔG4 clones than in parental Hep3B 
cells when grown in either normoxic (Fig. 2E) or 
hypoxic conditions. P1 and P2 transcripts were 
also detected in mRNA from normal kidney and 
liver (Fig. 2F). In kidney, the P1 transcript was 
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predominant, whereas in the liver, the long P2 
mRNA was predominant. In Hep3B cells, the 
presence of the ΔG mutation did not alter the 
rate of transcription from the P1 and P2 promot-
ers. However, the ΔG P2 mRNAs had a longer 
half-life than did the wild-type P2 mRNAs, 
which suggested that increased mRNA stability 
is responsible for the elevated levels of expres-
sion of P2 transcripts observed in Hep3B cells 
with the ΔG mutation (Fig. 2E). Additional in-
formation on the characterization of the P1 and 
P2 transcripts is provided in Figure S4 in the 
Supplementary Appendix.
To determine which transcripts are capable of 
producing erythropoietin, we transfected HEK293 
cells with complementary DNAs (cDNAs) repre-
senting P1 or P2 transcripts with or without the 
ΔG mutation and measured erythropoietin in cul-
ture supernatants. Cells transfected with ΔG P2 
transcripts produced more erythropoietin than 
cells transfected with wild-type P1 cDNA (Fig. S5A 
in the Supplementary Appendix). These superna-
tants also stimulated the growth of erythropoietin-
dependent BaF3-EpoR cells (Fig. S5B in the Supple-
mentary Appendix) and supported the growth of 
erythroid colonies from human peripheral blood 
(not shown), which showed that ΔG P2 tran-
scripts produce biologically active erythropoietin.
Translation of EPO mRNA Variants
We performed in vitro transcription–translation 
experiments and examined the composition of 
the open reading frames (ORFs) in EPO mRNAs 
to determine why more erythropoietin was pro-
duced by the short ΔG P2 cDNA construct than 
by the long ΔG P2 construct in transfected 
HEK293 cells (Fig. S5 in the Supplementary Ap-
pendix). In vitro translation of the short ΔG P2 
transcript produced more erythropoietin than 
did translation of the long ΔG P2 transcript or 
the wild-type P1 mRNA because the splicing 
event eliminates most of the upstream ORFs, 
which inhibit translation. Since AUG1* (the first 
start codon in the P2 transcripts; asterisks are 
used here to highlight start codons located in 
intron 1) is located within a sequence context 
that is predicted to be weak at initiating transla-
tion (Table S3 in the Supplementary Appendix),18 
ribosomes are likely to skip AUG1* and initiate 
translation from the next available start codon, 
which, in the short ΔG P2 transcript, is AUG2, 
located in exon 2. In vitro translation of the long 
ΔG P2 mRNA, most likely initiating from up-
stream AUG3* located in intron 1, produced a 
larger erythropoietin molecule that was approxi-
mately 25 kDa in size. The smaller observed 
protein product, which is approximately 21.6 kDa 
in size, is consistent with initiation of transla-
tion from AUG2. Removing upstream ORF1 by 
deleting the 5′ untranslated region (ΔUTR) in-
creased the translational efficiency of the wild-
type P1 mRNA, as reported previously.19 HEK293 
cells expressing the ΔG P1 cDNA produced low 
amounts of erythropoietin. A likely explanation 
is that ribosomes can skip the physiologic start 
codon (AUG1) in the ΔG P1 mRNA and initiate 
translation from AUG2, which connects with the 
erythropoietin coding sequence through the ΔG 
Figure 1 (facing page). Pedigree of the Family with 
 Hereditary Erythrocytosis and Identification of the 
 Mutation in EPO, the Gene Encoding Erythropoietin.
Panel A shows a pedigree of the family in this study. 
Unique patient numbers are placed under the symbols, 
with numbers below representing hemoglobin levels in 
grams per liter and the EPO sequence status indicated 
as wild-type (WT) or as having the c.32delG mutation 
(ΔG). Panel B shows hemoglobin levels plotted against 
erythropoietin (EPO) levels in serum. The green circles 
represent hemoglobin and EPO levels of 35 healthy per-
sons,13 and the green dashed line is the linear regression 
calculated from these values and represents the expect-
ed normal EPO level for a given hemoglobin level. The 
black dashed line indicates the hemoglobin level of 160 g 
per liter, which is the upper limit of the normal range 
among females. The gray shaded area indicates the 
normal range of EPO levels in serum. Panel C shows 
mapping of the disease-causing gene locus by the Affy-
metrix 250K single-nucleotide polymorphism (SNP) 
 array. Red, yellow, and blue boxes indicate genotype 
calls for each SNP in the array (with alleles at each SNP 
arbitrarily designated as A and B, red denotes AA, yel-
low AB, and blue BB). The vertical red line indicates a 
logarithm of the odds (LOD) score of 3.0. An enlarged 
view of the cosegregating region on chromosome 7 is 
shown on the right. The nucleotide positions of the 
two SNPs that mark the borders of the cosegregating 
region are also shown. Panel D shows chromatograms 
of the DNA sequences of the mutated locus. The het-
erozygous loss of one G nucleotide results in ambigu-
ous sequence reads downstream or upstream of the 
deleted G in the forward and reverse chromatograms, 
respectively. The red box indicates the location of the 
single-base deletion (ΔG). Panel E shows the location 
of the ΔG mutation and the resulting frameshift in the 
EPO mRNA. The wild-type EPO coding sequence is 
shown in red, and the sequences encoding the signal 
peptide and the mature protein are marked. The ΔG 
mutation induces a frameshift in the EPO mRNA se-
quence that truncates the signal peptide and generates 
a novel peptide, terminating after additional 51 amino 
acids (gray box). UTR denotes untranslated region.
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frameshift. Thus, erythropoietin protein from 
all ΔG transcripts appears to be produced by 
initiating translation from AUG2. Additional 
information on erythropoietin production by the 
P1 and P2 transcripts is provided in Figure S5 in 
the Supplementary Appendix.
Initiation of translation from AUG2 produces 
an erythropoietin protein with a shortened sig-
nal peptide (22 instead of 27 amino acids) and a 
novel N-terminal, which nevertheless was pre-
dicted by computer-based algorithm (SignalP 4.120) 
to be functional (Fig. S6 in the Supplementary 
Appendix). To test this prediction, we generated 
a cDNA construct representing EPO ΔG that starts 
directly with AUG2 and lacks any upstream 
AUGs. This construct (P2 ΔG ΔUTR) was most 
active in producing erythropoietin in vitro and 
in transfected HEK293 cells; it also showed bio-
Figure 2. Functional Characterization of the EPO ΔG Mutation.
Panel A shows chromatograms of EPO exon 2 DNA sequences from WT Hep3B and a CRISPR-modified single-cell clone. The region 
containing the ΔG deletion is indicated by the red box. Panel B shows concentrations of EPO in culture supernatants from Hep3B cells 
carrying the ΔG mutation. Parental Hep3B cells, Hep3B cells in which CRISPR failed to modify the EPO gene (WT), and Hep3B cells with 
EPO inactivated by a deletion and insertion (KO) are shown for comparison. EPO was measured by means of enzyme-linked immuno-
sorbent assay (ELISA), and EPO concentrations are given as means and standard deviations (T bars) of three biologic replicates. P values 
were determined by one-way analysis of variance. Panel C shows the biologic activity of EPO produced by parental Hep3B or CRISPR-
modified Hep3B cells, measured in culture supernatants by a proliferation assay with the BaF3-EpoR cell line. Serial dilutions of 2.5 IU 
per milliliter of recombinant human EPO (rhEPO) were used for reference (based on three biologic replicates). Panel D shows the EPO 
transcripts identified by 5′-RACE in Hep3B cells. The P1 transcript starts at exon 1, and its transcription is initiated from EPO promoter 1 
(P1). A putative promoter 2 (P2) is located in EPO intron 1. This promoter generates an alternative EPO transcript P2 (dark green) that 
can be further spliced to produce a short version of the P2 transcript (light green). Splice donor (SD) and splice acceptor (SA) sites are 
indicated with dashed lines. The GATA motif in the putative promoter is shown in red. The 5′ untranslated region (UTR) and the protein-
coding region (gray shading) are shown for the P1 transcript. Panel E shows quantification of EPO transcripts in CRISPR-modified and 
parental Hep3B cell lines by means of quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR). Values are the means and 
standard deviations (T bars) of four biologic replicates. of mRNA expression relative to expression of the parental P1 transcript, which 
was defined as 1. (For example, a value of 3 indicates expression 3 times as high as that of the parental P1 transcript, and a value of 0.5 
indicates expression half as high.) P values were determined by two-way analysis of variance. Panel F shows quantification by RT-qPCR 
of EPO transcripts in human kidney and liver RNA. Values represent means and standard deviations (T bars) of mRNA expression rela-
tive to expression of the P1 transcript in kidney, which was defined as 1. P values were determined by two-way analysis of variance.
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logic activity in the BaF3-EpoR proliferation 
assay (Fig. S5A and S5B in the Supplementary 
Appendix), which indicated that the shortened 
signal peptide is indeed functional.
Second EPO Allele Associated 
with Erythrocytosis
A father and daughter with erythrocytosis and a 
single C nucleotide deletion (ΔC) of unknown 
significance, which was located in EPO exon 2 just 
13 nucleotides upstream of ΔG (c.19delC; chro-
mosome 7: 100,319,185 TC→T), were recently de-
scribed.11 To test whether EPO ΔC has the same 
effect as EPO ΔG, we generated ΔC P2 cDNA 
constructs, transfected HEK293 cells, and mea-
sured erythropoietin protein and erythropoietin 
bioactivity in cell-culture supernatants. The long 
P2 and short P2 transcripts with the ΔC mutation 
also produced high amounts of erythropoietin 
that was biologically active (Fig. S7 in the Supple-
mentary Appendix), which showed that the EPO 
ΔC mutation causes erythrocytosis through the 
same mechanism (Fig. 3) as the EPO ΔG mutation.
Discussion
We propose that the frameshift mutation ΔG in 
EPO causes erythrocytosis on the basis of ge-
netic linkage with a locus on chromosome 7q21 
(LOD score, 3.3), functional data, and our find-
ing of a second, independent allele (ΔC) in a fa-
ther and daughter with erythrocytosis. Both ΔG 
and ΔC cause a frameshift and convert a non-
coding mRNA transcribed from an alternative 
(P2) promoter inside EPO intron 1 into an mRNA 
that produces functional erythropoietin protein. 
This frameshift occurs in the sequence encoding 
the signal peptide of erythropoietin; the mutant 
peptide sequence is fully functional. We dissected 
the relative contribution of individual upstream 
AUG start codons located in the 5′ untranslated 
regions of P1 and P2 transcripts and established 
that erythropoietin protein from both P2 ΔG 
transcripts appears to be produced by initiating 
translation from AUG2, located in exon 2.
P2 transcripts were more abundant in normal 
liver than in kidney, which suggested that the 
Figure 3. Model and Proposed Mechanism for EPO Overproduction by a Single-Nucleotide Deletion in Exon 2 of EPO.
The exons of EPO are numbered and drawn as boxes. Open boxes represent 5′ and 3′ UTRs. Panel A shows the 
wild-type gene producing EPO from P1 transcripts (black boxes), whereas P2 promoter transcripts generate only a 
short, nonfunctional peptide (blue box). Panel B shows the effects of the frameshift caused by a single-nucleotide 
deletion in exon 2 of EPO (ΔG or ΔC). The mutated P1 transcripts produce only a short nonfunctional peptide ter-
minating in exon 3 (black boxes), and minimal amounts of EPO can be produced if translation is initiated from an 
alternative AUG2 start site (see Fig. S5A in the Supplementary Appendix). P2 transcripts (blue box) connect through 
the frameshift to the EPO coding sequence (black boxes) and are responsible for the overproduction of EPO. Gray 
boxes represent EPO coding sequences that are in a different reading frame.
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main source of erythropoietin production in af-
fected family members was the liver. Indeed, P2 
transcripts are present in human liver RNAseq 
data sets from ProteinAtlas21 and the Illumina 
Human Body Map (Fig. S8 in the Supplementary 
Appendix). In a database of capped 5′ ends of 
mRNAs,22,23 P2 transcripts were the predominant 
mRNA species in the liver, whereas P1 transcripts 
were mainly detected in RNA from kidney (Fig. 
S9 in the Supplementary Appendix). The physi-
ological function of wild-type P2 transcripts is 
currently unknown, but it seems likely that they 
do have a function, because EPO intron 1 has a 
high degree of sequence homology between hu-
man and mouse and the region of homologous 
sequence extends upstream of the P2 promotor 
(Fig. S10 in the Supplementary Appendix).24
Our data indicate that the EPO ΔG mutation 
prematurely terminates translation of EPO P1 
transcripts, whereas it alters the normally non-
coding P2 transcripts such that AUG2 initiates 
translation of the erythropoietin coding sequence 
and produces an excess of biologically active 
erythropoietin. Mutations in EPO should be con-
sidered in the search for causes of inherited 
erythrocytosis. More generally, the effect of muta-
tions on multiple mRNA transcripts may explain 
nonintuitive relationships between phenotype 
and the ostensible mechanism predicted by the 
mutation.
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Supplementary methods 
Patient samples and measurements of blood parameters 
Measurements of Hb, leukocytes, platelets and Epo were carried out at the Department of 
Medical Biochemistry, St. Olavs Hospital, Trondheim, Norway during the time period of 1966-
2017. 80 % of the measurements have been carried out during a time when the normal range 
of Hb has been 117 - 153 g/L in women and 134 - 165 or 170 g/L in Men. The normal range 
for Epo in serum was 3.7 - 31.5 IU/L. 
Linkage analysis and next generation sequencing 
We performed parametric linkage analysis using Affymetrix SNP 250K arrays, and dChip 
software1 for linkage analysis. Next generation sequencing was performed using Agilent 
SureSelect Target Enrichment designed to capture exons and intron/exon boundaries of co-
segregating regions. CLC Genomic Workbench was used for alignment and variant detection 
comparing against the human reference genome build hg19. 
Microsatellite mapping 
10 FAM-labelled microsatellite markers (sequences in Supplementary Table 4) spanning from 
q21.11 (D7S669) to q32.2 (D7S530) on chromosome 7 were used for genotyping of 18 
members of the family. PCR was performed with Q5 High-Fidelity DNA Polymerase (NEB) and 
subsequently analysed on an ABI 3130xl Genetic Analyzer (Applied Biosystems). Data 
collection and allele identification were performed using GeneMapper v5.0 software (Applied 
Biosystems).  
EPO gene sequence analysis 
Primers flanking exon 2 of human EPO (fwd: 5’-GCCACCACTTATCTGCCA-3’, rev: 5’-
AACTCCACCCCAAACCAA-3’) were used for PCR amplification with Q5 High-Fidelity DNA 
Polymerase (NEB). PCR products were purified with Exonuclease I and Thermosensitive 
Alkaline Phosphatase mix (Thermo Fisher) by incubating 15min. at 37°C followed by 85°C for 
15min. Reactions were submitted for Sanger sequencing to Microsynth. Sequences were 
analysed with CLC Main Workbench 7.7.1 (Qiagen).  
Cell lines and transfections 
Human hepatocellular carcinoma cell line Hep3B (kindly provided by Drs. Luca Quagliata and 
Cristina Quintavalle from Institute of Pathology, University Hospital Basel) was maintained in 
RPMI media with L-glutamine and HEPES (GIBCO Invitrogen) supplemented with 10% fetal 
bovine serum (Sigma) and Penicillin-Streptomycin mix (GIBCO Invitrogen). Genomic DNA was 
isolated with QIAamp DNA mini kit (Qiagen) and sent for STR genotyping to Microsynth that 
3 
confirmed Hep3B identity and excluded contamination with other human cell lines. 
HEK293LTV cell line (Cell Biolabs) was maintained in high glucose DMEM with L-glutamine 
supplemented with 10% fetal bovine serum (Sigma) and Penicillin/Streptomycin mix (GIBCO 
Invitrogen). BaF3-EpoR cells were cultured in RPMI media same as Hep3B with 10% 
conditioned medium of WEHI-3 cell line. Cells were grown at 37 °C in 5 % CO2 humidified 
atmosphere with 21% O2. For hypoxia experiments, Hep3B cells were shifted to 1% O2, 5% 
CO2 for 72 hours, if not stated otherwise. For overexpression experiments, 2,5x105 cells per 
well (6-well plates) were transfected with 0.5 μg of the plasmid using jetPRIME reagent 
(Polyplus Transfection) and supernatants were harvested 72 hours post transfection.  
Single-guide RNA (sgRNA) cloning 
Single-guide RNA targeting exon 2 of EPO was designed with Zhang algorithm (crispr.mit.edu) 
and cloned into pSpCas9(BB)-2A-GFP (pX458) vector (obtained from Addgene) using primers 
in Supplementary Table 4 and following previously established protocol.2  
CRISPR-mediated EPO locus targeting  
5 μg of targeting vector was premixed with 100 pmoles of 150 bp single-stranded oligo donor 
template (Integrated DNA Technologies) and electroporated into 1x106 Hep3B cells per 
condition using Cell Line Nucleofactor Kit V (Lonza). GFP-positive cells were sorted 48 hours 
post nucleofection as a bulk and expanded for 1 week in culture. After expansion, cells were 
divided into pools and genomic DNA was isolated using QIAamp DNA mini kit (Qiagen). To 
assess, which pools contain the highest frequency of mutated cells, SNP genotyping assay 
(Applied Biosystems) was performed using custom primers and TaqMan probes (sequences in 
Supplementary Table 4). SNP genotyping PCR was performed on ABI 7500 Fast Real-Time 
PCR System (Applied Biosystems) with 15ng of genomic DNA using 2x TaqMan Universal 
PCR Master Mix (Applied Biosystems). 
Cell pools with highest frequency of mutated cells were single-cell sorted into 96-well plates 
coated with Collagen Solution (StemCell Technologies) and cultured in 1:1 fresh RPMI media 
and Hep3B-conditioned RPMI media. Genomic DNA was isolated by incubating cells in DNA 
lysis buffer (50mM KCl, 10mM Tris pH8, 0.45% Tween-20, 0.45% NP-40 and 20mg/ml 
proteinase K) at 65°C for 60min. followed by 10min. at 95°C. 5μl of mixture were used for EPO 
exon 2 PCR followed by Sanger sequencing as described above. 
To confirm both alleles of EPO were successfully targeted, PCR products were subcloned with 
Zero Blunt PCR Cloning Kit (Invitrogen), transformed into the NEB 5-alpha Competent E.coli 
(NEB), plasmid DNA was isolated using NucleoSpin Plasmid kit (Macherey-Nagel) and send 
out for sequencing to Microsynth. Sequences were analysed with CLC Main Workbench 7.7.1 
(Qiagen).  
4 
CRISPR off-target analysis 
CRISPR-edited Hep3B clones were tested for off-target editing events predicted for sgRNA by 
the Zhang laboratory algorithm (crispr.mit.edu) and the COSMID tool 3 
(crispr.bme.gatech.edu). The top-five non-overlapping predicted off-target sites were used 
from each tool (Supplementary Table 5). Regions surrounding each off-target site were PCR-
amplified using primers in Supplementary Table 4, Sanger sequenced as described above and 
compared to the unedited parental cell line.  
Epo levels measurement 
Cell supernatants from Hep3B cell lines cultured under normoxia and hypoxia were sterile-
filtered (0.22μm) and Epo levels were measured with human erythropoietin Legend Max 
ELISA Kit (Biolegend). Epo levels were normalized to the protein concentration in the cell 
lysate. Cell supernatants from transfected HEK293LTV cells were sterile-filtered (0.22μm) and 
Epo levels were measured with Human EPO Tissue Culture Kit (Meso Scale Discovery) on 
MESO Sector S 600 device equipped with Discovery Workbench 4.0 software. 
Proliferation assay 
Cell proliferation rates were measured by using CellTiter-Glo Luminiscent Cell Viability Assay 
(Promega). Supernatants from Hep3B cell lines and transfected HEK293LTV cells were used 
to stimulate the growth of BaF3-EpoR cell line. Recombinant human Epo (Peprotech) was 
used as a positive control. BaF3-EpoR cells were washed 3 times with PBS and 5x103 cells 
per well were plated into 96-well plates and incubated in RPMI + 10% FBS with either 2- or 10-
fold dilution of cell supernatants or recombinant human Epo for 72 hours. Then 30μl of cells 
were transferred into black opaque 96-well plates (Eppendorf) and incubated with equal 
volume of Cell-Titer-Glo Reagent according to the manufacturer’s protocol. Luminiscence was 
measured on Synergy H1 microplate reader (Biotek) equipped with Gen5 v2.05 software.   
5’ rapid amplification of cDNA ends (5’RACE) 
Total RNA from parental and CRISPR-edited Hep3B cell lines isolated with TriFast (VWR 
International) together with total RNA from human kidney and liver (Takara Clontech) were 
subjected to 5’RACE with SMARTer RACE 5’/3’ Kit (Takara Clontech) according to the 
manufacturer’s protocol with the following gene specific primers for human EPO: GSP1: 5’-
GATTACGCCAAGCTTAGCAGTGATTGTTCGGAGTGGAGCAG and GSP 2-
GATTACGCCAAGCTTAGAGCCCGAAGCAGAGTGGTGAGGC, gene-specific part in bold. 
RACE products were further subcloned and transformed, plasmid DNA from bacterial colonies 
was isolated using Zyppy-96 Plasmid Miniprep (Zymo Research) and Sanger sequenced. The 
sequencing reads were mapped to reference gene variant with CLC Main Workbench 7.7.1 
(Qiagen).  
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Cloning of EPO constructs and site-directed mutagenesis 
EPO transcripts were amplified from Hep3B cDNA with primers listed in Supplementary Table 
4 with Q5 High-Fidelity DNA Polymerase mix (NEB). PCR products were purified from agarose 
gel with NucleoSpin Gel and PCR Clean-up (Macherey-Nagel) and subsequently cloned into 
pcDNA3 vector (Invitrogen). For introducing ΔG and ΔC mutations into the plasmids, 
QuickChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies) was used 
with primers listed in Supplementary Table 4. Plasmid sequences were verified with Sanger 
sequencing and midiprep DNA was produced with NucleoBond Xtra Midi kit (Macherey-Nagel). 
EPO transcripts quantitation 
Total RNA from parental and CRISPR-edited Hep3B cell lines isolated with TriFast (VWR 
International) and together with total RNA from human kidney and liver (Takara Clontech and 
AMS Biotechnology) was reverse-transcribed with High Capacity cDNA Reverse Transcription 
Kits (Applied Biosystems). cDNA was amplified with Power SYBR Green PCR Master Mix 
(Applied Biosystems) and primers listed in Supplementary Table 4 on ViiA 7 Real-Time PCR 
System (Applied Biosystems). Relative gene expression change was calculated according to 
ΔΔCt method using GUSB gene for normalization.  
RNA transcription rate 
To investigate RNA transcription rates, Hep3B cells were plated at density 1,5x105 cells per 
well (12-well plates) and 24 hours later, 0.5mM of 5-ethynyl uridine (5-EU) was added to the 
cells with fresh media for 30min. Nascent RNAs were captured by using the Click-iT Nascent 
RNA Capture Kit (Invitrogen) in accordance with the manufacturer’s instructions. 
RNA stability 
Stability of EPO mRNAs was examined as described previously.4 Briefly, Hep3B cells were 
plated at density 2,5x105 cells per well (6-well plates) and first incubated in hypoxic chamber 
(1%O2, 5% CO2) for 48 hours and then switched to the normoxia (21%O2, 5% CO2). Cells 
were collected at 0, 1, 2, 3, 4, 6 and 8 hrs after the switch to normoxia. RNA isolation, cDNA 
synthesis and qRT-PCR was performed as described above.  
In vitro transcription and translation 
EPO constructs in pcDNA3 vector were linearized with XhoI, extracted with phenol-
chloroform and ethanol-precipitated. 1μg of linearized DNA was used as a template for in 
vitro transcription using T7 MEGAScript kit (Thermo Fisher Scientific). Reactions were 
incubated for 4 hrs at 37°C, followed by DNase treatment and phenol-chloroform extraction. 
Identity of the different EPO transcripts was verified by Agilent 2100 Bioanalyzer. 2.5ug of 
each EPO mRNA was translated for 2hrs at 25°C using wheat germ extract lysate 
6 
(Promega) in the presence of FluoroTect Green in vitro Translation Labeling System 
(Promega). Labelled proteins were separated on NuPAGE 12% Bis-Tris Protein gels 
(Invitrogen) and visualized on Typhoon 9400 Imaging System (GE Healthcare Life 
Sciences) using 488nm laser and 526SP emission filter.  
Bioinformatics analysis 
RNAseq reads were downloaded from the Human Protein Atlas 5 or Illumina Body Map, 3’ 
adapters were trimmed using Cutadapt. 6 The trimmed reads were mapped (only mate 1 
was used) to the human genome using the STAR aligner (version 2.5.3a) with default 
parameters. 7 The ENSEMBL (version 87) annotation file was used. 8 The mapped reads 
were then sorted and indexed using SAMtools (version 1.3). 9 Processed and aligned 
CAGE-sequencing data were downloaded from FANTOM5 project. 10,11 Read coverage was 
generated with IGV v2.3. 12 
Statistical analysis 
Statistical significance of the data was tested with one-way ANOVA or two-way ANOVA and 
analysed using GraphPad Prism 7 software with the following significance levels: p<0.05= *, 
p<0.01= ** and p<0.001= ***. 
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Supplementary Figure S1. Co-segregation of microsatellite markers on chromosome 7q22.1 with the 
erythrocytosis phenotype. Schematic drawing of the pedigree with unique patient numbers placed under the 
symbols and EPO gene sequence status indicated as wildtype (WT) or mutated (ΔG). Haplotypes for ten 
polymorphic markers from D7S669 to D7S530 are shown for each family member. The minimal co-
segregating region is marked in red and the haplotype linked with the disease is boxed. Physical position of 
microsatellite markers (STR) on chromosome 7 is shown. Microsatellite markers defining the co-segregating 
region are shown in red. Two SNPs marking the borders of the co-segregating region identified by SNP array 
(see Figure 1C) are shown for the comparison.  
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Supplementary Figure S2. Introducing the EPO ΔG mutation into Hep3B cells by CRISPR. A) CRISPR-
mediated mutagenesis of the EPO locus in Hep3B cells. The homology-directed repair (HDR) donor DNA is a 
150 base pair (bp) single-stranded oligodeoxynucleotide that is complementary to the target sequence and 
contains a 1 bp deletion (ΔG), shown in a red box. This modification is flanked by asymmetrical homology 
arms at 5’ and 3’ ends. Single-guide RNA targeting sequence is depicted in light blue and protospacer 
adjacent motif (PAM) in orange. B) Sequencing chromatograms of Hep3B clones modified by CRISPR. 
Deletions or insertions are marked with red dashed lines. The single-guide RNA (sgRNA) targeting sequence 
is depicted in light blue and the protospacer adjacent motif (PAM) in orange.  
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Supplementary Figure S3. Functional characterization of Hep3B-CRISPR clones under the hypoxia. A) 
Epo protein production by Hep3B clones. Supernatants of parental or CRISPR-modified HepB3 cells 
incubated in hypoxic conditions (1%O2, 5% CO2) for 72 hours and were collected and Epo protein was 
measured by Epo ELISA. The levels of Epo are given as a mean ± SD (n=3), p < 0.05 = *, as determined by 
one-way ANOVA. B) Biological activity of Epo in supernatants of parental or CRISPR-modified HepB3 cells 
incubated in hypoxic conditions (1%O2, 5% CO2) for 72 hours was measured by a proliferation assay with 
BaF3-EpoR cell line. Serial dilutions of 2.5 IU/ml of recombinant human Epo were used for the reference, n=3. 
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Supplementary Figure S4. Characterization of EPO P1 and P2 transcripts. A) Sequences of a putative 
promoter P2 in EPO intron 1 and chromatograms of P2 mRNA sequences identified by 5’-RACE of human 
liver RNA. The location of a putative P2 promoter is marked by an arrow and two GATA-consensus motifs are 
highlighted in red. The sequence of the longest P2 transcript identified by 5’-RACE is indicated by green bar, 
exon 2 sequences by a grey bar. A short version of P2 transcript is produced by splicing out the region of 
intron 1 marked by splice donor (SD) and splice acceptor (SA) sites (yellow circles). B) Quantification of 
different EPO transcripts in Hep3B cells by qRT-PCR in hypoxic conditions.  Total RNA from CRISPR-modified 
and parental HepB3 cell lines incubated in hypoxic conditions (1%O2, 5% CO2) for 72 hours was used. 
Values are means ± SD (n=2), p < 0.05 = *, as determined by two-way ANOVA. C) Transcription rate of EPO 
mRNAs. Quantification of nascent wildtype (WT) and mutant (ΔG) EPO mRNAs in Hep3B parental cells (black 
bars) and ΔG cells (red bars). 5-EU labelled transcripts were quantified by qRT-PCR. Values are means ± SD 
(n=3). (D) Determination of the stability of EPO transcripts. The stability of EPO mRNAs was examined in 
Hep3B parental cells (black points) or ΔG cells (red points). EPO expression levels were measured by qRT-
PCR and are displayed as a percentage of the levels at the time point 0 h, which is defined as 100%. Values 
are means ± SD (n=3). Decay curves are non-linear one phase decay fit. Half-life of mRNA (t1/2) is an 
estimation of time, in which 50% of existing mRNA molecules is degraded.  
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Supplementary Figure S5.  Epo protein production by EPO P1 and P2 transcripts. A) Upper part: Epo 
protein measured by immunoassay in supernatants of HEK293 transfected with cDNAs representing P1 or P2 
transcripts or empty vector. The levels of Epo are given as a mean ± SD (n=4), p < 0.05 = *, p < 0.01 = **,  p < 
0.001 = *** as determined by one-way ANOVA. An enlarged view of the results of the P1 transcripts is shown 
to the right. Lower part: In vitro transcription-translation of EPO mRNAs. Equal amounts of in vitro transcribed 
EPO mRNA variants (bottom) were used for in vitro translation in wheat germ lysates in the presence of 
fluorescently labelled lysine. Epo proteins separated by SDS-gel electrophoresis and visualized by fluorescent 
imager are shown on top. The predicted molecular weight of wildtype Epo protein including signal peptide is 
21.3 kDa. Epo protein with ΔG mutation is shortened by 5 amino acids and expected to be 20.6 kDa. The 
cause for lower MW bands in the ΔG short and DUTR lanes is unknown. A higher molecular weight band of 
~25 kDa present in the lane for P2 long ΔG mRNA most likely represents Epo protein initiating from the 
upstream AUG3* that is in frame with the Epo reading frame. B) Supernatants of transfected HEK293 cells 
contain biologically active Epo protein. Epo activity was measured by a proliferation assay with BaF3-EpoR 
cell line. Serial dilutions of 100 IU/ml of recombinant human Epo were used for reference, n=4. C) Schematic 
drawing showing the translational reading frames of EPO P1 and P2 transcripts and the consequences of the 
ΔG mutation on the EPO expression. The upper panel represents the P1 transcript with or without ΔG 
mutation and an artificial P1 ΔUTR construct lacking uORF1. The lower panel shows the P2 transcripts with or 
without ΔG mutation and an artificial P2 ΔG ΔUTR construct starting with AUG2 as a first available initiation 
codon. The translational start codons (AUG) are numbered and placed in the corresponding reading frames. 
AUGs located in intron 1 are marked by an asterisk (*). Red dotted line denotes the position of the ΔG 
mutation. Splice donor (SD) and splice acceptor (SA) sites in intron 1 are drawn as yellow circles and the 
splicing event that generates the EPO short mRNA is marked by dashed lines. Dashed blue lines mark the 
position of spliced intron-exon 2 junctions. 
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Supplementary Figure S6. Functional prediction of Epo WT, Epo ΔG and Epo ΔC signal peptides. 
Comparison of Epo WT, Epo ΔG and Epo ΔC signal peptides (SPs) predicted by SignalP 4.1 algorithm. 13 
Algorithm produces three output scores for each amino acid in the sequence. The C-score (raw cleavage site 
score) is high at the position immediately after the cleavage site, S-score (signal peptide score) distinguishes 
SPs from the mature part of the proteins. Y-score (combined cleavage site score) is a combination of the C-
score and the slope of the S-score. A weighted average of the mean S- and maximal Y-scores is used to 
generate a D-score (discrimination score) that discriminates signal peptides from non-signal peptides. D-score 
> 0.450 predicts a signal peptide. SPs are marked in blue, mature Epo peptide in black. N-terminal parts of
Epo ΔG and Epo ΔC SPs that differ from WT are highlighted in red.
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Supplementary Figure S7. EPO c.19delC (ΔC) mutation also causes overproduction of Epo. A) 
Schematic drawing showing the location and the consequences of the ΔC mutation on the EPO P2 
transcripts. B) Measurement of Epo protein levels and C) Epo biological activity of the supernatants from 
HEK293 cells transfected with EPO P1 and P2 transcripts cDNA with ΔC mutant constructs, similar to 
Figure S5A and S5B. Note that the results of the wildtype P1 EPO construct, the wildtype ΔUTR construct, 
and the empty vector and rhEPO controls are duplicated and shown for reference also in Supplementary 
Figure S5. 
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Supplementary Figure S8. EPO P2 transcripts in RNA sequencing data of human kidney and liver. RNAseq reads were downloaded from the 
Human Protein Atlas 5 or Illumina Body Map, data were processed as described in Methods section and read coverage was generated with IGV 
v2.3.12 
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Supplementary Figure S9. EPO P1 and P2 transcripts in CAGE-sequencing data of human and mouse kidney and liver. CAGE-sequencing 
data from FANTOM5 project 10,11 mapped to the reference genomes. Read coverage was generated with IGV v2.3.12 Transcriptional start sites for 
P1 are marked with a blue frame and P2 transcripts are marked with a red frame. Arrows denote 5’->3’ orientation. 
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Supplementary Figure S10. Intron 1 of EPO gene is conserved between the human and the mouse. Alignment of human and mouse EPO DNA 
sequences as calculated by mVISTA 14, using 100 bp window size is shown in upper panel. Regions in red show at least 70% homology. Promoter (P) 
region is depicted as a yellow box, CDS as grey boxes, 5’- and 3’-untranslated regions as white boxes and intron 1 as a green box. P1 and P2 
translational start sites (TSS) are showed with the arrow and red dotted line. Exons are showed with the black dotted line. Lower panel shows the 
closer look on the part of the intron 1, upper sequence is of human origin, lower of a mouse origin. Two GATA-consensus motifs are shown in red 
frames, P2 TSS is shown with an arrow and sequence in red is conserved between the human and the mouse. 
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Supplementary Table 1. Blood parameters of the family members. 
UPN Gender Age at ΔG Hb WBC Plt Epo 
diagnosis g/L x109/L x109/L IU/L 
WG01 F 24 ΔG 197 8.2 176 14.6 
WG02 M 25 ΔG 204 6.2 238 17.2 
WG04 F 16 ΔG 183* 5.6 262 14.5 
WG05 M 27 ΔG 167 6.8 197 9.3 
WG06 F 7 ΔG 174* 5.9 194 37.7 
WG08 F 53 ΔG 198 7.1 176 39.0 
WG11 M 21 ΔG 215 3.1 173 51.2 
WG14 F 8 ΔG 180* 5.9 386 84.6 
WG15 F 15 ΔG 187* 5.2 365 12.6 
WG20 F 1.5 ΔG 200 9.6 263 na 
WG03 M WT 155 8.0 176 8.8 
WG09 M WT 158 7.0 205 11.0 
WG12 F WT 152 8.5 336 na 
WG13 M WT 146 9.0 280 na 
WG17 M WT 145 5.8 242 na 
WG18 M WT 152 6.5 205 na 
WG19 F WT 131 5.7 280 13.4 
WG21 M WT 117 8.9 401 7.1 
* Hb are values at diagnosis, except for WG04, WG06, WG14
and WG15 that represent the highest value recorded after the
start of phlebotomy
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Supplementary Table 2. Gene list of co-segregating region identified by SNP array. 
Chr 
Start 
position 
End 
position Gene name Gene description 
chr7 95401817 95727736 DYNC1I1 Homo sapiens dynein, cytoplasmic 1, intermediate chain 1 (DYNC1I1), transcript variant 1, mRNA. 
chr7 95749531 95951459 SLC25A13 Homo sapiens solute carrier family 25 (aspartate/glutamate carrier), member 13 (SLC25A13), 
nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
chr7 95848973 95849068 MIR591 Homo sapiens microRNA 591 (MIR591), microRNA. 
chr7 95936144 95936164 JB074828 Sequence 777 from Patent WO2010139812. 
chr7 95970451 95970558 U6 Rfam model RF00026 hit found at contig region AC004458.1/138309-138203 
chr7 96110937 96132835 C7orf76 Homo sapiens chromosome 7 open reading frame 76 (C7orf76), transcript variant 1, mRNA. 
chr7 96250968 96293650 LOC100506136 Homo sapiens uncharacterized LOC100506136 (LOC100506136), non-coding RNA. 
chr7 96318078 96339203 SHFM1 Homo sapiens split hand/foot malformation (ectrodactyly) type 1 (SHFM1), mRNA. 
chr7 96569378 96569676 Metazoa_SRP Rfam model RF00017 hit found at contig region AC004774.1/46257-45960 
chr7 96594613 96594793 Evf1_1 Rfam model RF01887 hit found at contig region AC004774.1/71195-71374 
chr7 96594800 96595007 Evf1_2 Rfam model RF01888 hit found at contig region AC004774.1/71382-71588 
chr7 96597826 96643377 DLX6-AS1 Homo sapiens DLX6 antisense RNA 1 (DLX6-AS1), non-coding RNA. 
chr7 96635289 96640352 DLX6 Homo sapiens distal-less homeobox 6 (DLX6), mRNA. 
chr7 96649701 96654143 DLX5 Homo sapiens distal-less homeobox 5 (DLX5), mRNA. 
chr7 96745904 96811075 ACN9 Homo sapiens ACN9 homolog (S. cerevisiae) (ACN9), mRNA. 
chr7 97228244 97228572 7SK Rfam model RF00100 hit found at contig region AC003085.2/78764-78437 
chr7 97361270 97369784 TAC1 Homo sapiens tachykinin, precursor 1 (TAC1), transcript variant beta, mRNA. 
chr7 97481428 97501854 ASNS Homo sapiens asparagine synthetase (glutamine-hydrolyzing) (ASNS), transcript variant 2, mRNA. 
chr7 97503666 97601638 MGC72080 Homo sapiens MGC72080 pseudogene (MGC72080), non-coding RNA. 
chr7 97595943 97596475 BC122864 Homo sapiens cDNA clone IMAGE:40108680. 
chr7 97614012 97619416 OCM2 Homo sapiens oncomodulin 2 (OCM2), mRNA. 
chr7 97736196 97838944 LMTK2 Homo sapiens lemur tyrosine kinase 2 (LMTK2), mRNA. 
chr7 97841567 97842271 BHLHA15 Homo sapiens basic helix-loop-helix family, member a15 (BHLHA15), mRNA. 
chr7 97844754 97881563 TECPR1 Homo sapiens tectonin beta-propeller repeat containing 1 (TECPR1), mRNA. 
chr7 97910978 97920839 BRI3 Homo sapiens brain protein I3 (BRI3), transcript variant 1, mRNA. 
chr7 97920961 98030427 BAIAP2L1 Homo sapiens BAI1-associated protein 2-like 1 (BAIAP2L1), mRNA. 
chr7 97937196 97938205 hCG_2023280 SubName: Full=HCG2023280; SubName: Full=cDNA FLJ30064 fis, clone ADRGL2000323; 
chr7 98246596 98259181 NPTX2 Homo sapiens neuronal pentraxin II (NPTX2), mRNA. 
chr7 98444110 98467673 TMEM130 Homo sapiens transmembrane protein 130 (TMEM130), transcript variant 1, mRNA. 
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chr7 98476112 98610866 TRRAP Homo sapiens transformation/transcription domain-associated protein (TRRAP), transcript variant 1, mRNA. 
chr7 98479272 98479352 MIR3609 Homo sapiens microRNA 3609 (MIR3609), microRNA. 
chr7 98625057 98741743 SMURF1 Homo sapiens SMAD specific E3 ubiquitin protein ligase 1 (SMURF1), transcript variant 1, mRNA. 
chr7 98771196 98805089 KPNA7 Homo sapiens karyopherin alpha 7 (importin alpha 8) (KPNA7), mRNA. 
chr7 98870923 98895594 MYH16 Homo sapiens myosin, heavy chain 16 pseudogene (MYH16), non-coding RNA. 
chr7 98923495 98963885 ARPC1A Homo sapiens actin related protein 2/3 complex, subunit 1A, 41kDa (ARPC1A), transcript variant 1, mRNA. 
chr7 98972297 98992404 ARPC1B Homo sapiens actin related protein 2/3 complex, subunit 1B, 41kDa (ARPC1B), mRNA. 
chr7 98992297 99006305 PDAP1 Homo sapiens PDGFA associated protein 1 (PDAP1), mRNA. 
chr7 99006600 99017239 BUD31 Homo sapiens BUD31 homolog (S. cerevisiae) (BUD31), mRNA. 
chr7 99014361 99063824 ATP5J2-PTCD1 Homo sapiens ATP5J2-PTCD1 readthrough (ATP5J2-PTCD1), mRNA. 
chr7 99036562 99054996 CPSF4 Homo sapiens cleavage and polyadenylation specific factor 4, 30kDa (CPSF4), transcript variant 1, mRNA. 
chr7 99067306 99067378 TRNA_Trp transfer RNA Trp (anticodon CCA) 
chr7 99070514 99085217 ZNF789 Homo sapiens zinc finger protein 789 (ZNF789), transcript variant 1, mRNA. 
chr7 99090853 99097877 ZNF394 Homo sapiens zinc finger protein 394 (ZNF394), mRNA. 
chr7 99102272 99131445 ZKSCAN5 Homo sapiens zinc finger with KRAB and SCAN domains 5 (ZKSCAN5), transcript variant 2, mRNA. 
chr7 99143922 99149757 FAM200A Homo sapiens family with sequence similarity 200, member A (FAM200A), mRNA. 
chr7 99156447 99174076 ZNF655 Homo sapiens zinc finger protein 655 (ZNF655), transcript variant 8, mRNA. 
chr7 99195901 99208456 LOC100289187 Homo sapiens transmembrane protein 225-like (LOC100289187), transcript variant 2, mRNA. 
chr7 99214570 99230030 ZSCAN25 Homo sapiens zinc finger and SCAN domain containing 25 (ZSCAN25), mRNA. 
chr7 99282301 99332819 
CYP3A7-
CYP3AP1 Homo sapiens CYP3A7-CYP3AP1 readthrough (CYP3A7-CYP3AP1), mRNA. 
chr7 99354582 99381811 CYP3A4 Homo sapiens cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4), transcript variant 1, mRNA. 
chr7 99425635 99464173 CYP3A43 Homo sapiens cytochrome P450, family 3, subfamily A, polypeptide 43 (CYP3A43), transcript variant 1, mRNA. 
chr7 99473684 99474656 OR2AE1 Homo sapiens olfactory receptor, family 2, subfamily AE, member 1 (OR2AE1), mRNA. 
chr7 99488029 99517223 TRIM4 Homo sapiens tripartite motif containing 4 (TRIM4), transcript variant beta, mRNA. 
chr7 99520891 99527243 GJC3 Homo sapiens gap junction protein, gamma 3, 30.2kDa (GJC3), mRNA. 
chr7 99564349 99573735 AZGP1 Homo sapiens alpha-2-glycoprotein 1, zinc-binding (AZGP1), mRNA. 
chr7 99578384 99591588 AZGP1P1 Homo sapiens alpha-2-glycoprotein 1, zinc-binding pseudogene 1 (AZGP1P1), non-coding RNA. 
chr7 99613218 99635403 ZKSCAN1 Homo sapiens zinc finger with KRAB and SCAN domains 1 (ZKSCAN1), mRNA. 
chr7 99647416 99662663 ZSCAN21 Homo sapiens zinc finger and SCAN domain containing 21 (ZSCAN21), mRNA. 
chr7 99667593 99679387 ZNF3 Homo sapiens zinc finger protein 3 (ZNF3), transcript variant 2, mRNA. 
chr7 99686582 99689822 COPS6 Homo sapiens COP9 signalosome subunit 6 (COPS6), mRNA. 
chr7 99690403 99699427 MCM7 Homo sapiens minichromosome maintenance complex component 7 (MCM7), transcript variant 1, mRNA. 
chr7 99691182 99691266 MIR25 Homo sapiens microRNA 25 (MIR25), microRNA. 
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chr7 99691390 99691470 MIR93 Homo sapiens microRNA 93 (MIR93), microRNA. 
chr7 99691437 99691459 DD413568 Sequence 150 from Patent WO2004076622. 
chr7 99691615 99691697 MIR106B Homo sapiens microRNA 106b (MIR106B), microRNA. 
chr7 99699129 99704803 AP4M1 Homo sapiens adaptor-related protein complex 4, mu 1 subunit (AP4M1), mRNA. 
chr7 99704692 99717481 TAF6 Homo sapiens TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 80kDa (TAF6), transcript variant 5, mRNA. 
chr7 99717264 99723128 CNPY4 Homo sapiens canopy 4 homolog (zebrafish) (CNPY4), mRNA. 
chr7 99724319 99726121 MBLAC1 Homo sapiens metallo-beta-lactamase domain containing 1 (MBLAC1), mRNA. 
chr7 99746529 99751833 LAMTOR4 Homo sapiens late endosomal/lysosomal adaptor, MAPK and MTOR activator 4 (LAMTOR4), mRNA. 
chr7 99752042 99756302 C7orf43 Homo sapiens chromosome 7 open reading frame 43 (C7orf43), mRNA. 
chr7 99756864 99766373 GAL3ST4 Homo sapiens galactose-3-O-sulfotransferase 4 (GAL3ST4), mRNA. 
chr7 99767228 99774990 GPC2 Homo sapiens glypican 2 (GPC2), mRNA. 
chr7 99775537 99812010 STAG3 Homo sapiens stromal antigen 3 (STAG3), mRNA. 
chr7 99798277 99869855 GATS Homo sapiens GATS, stromal antigen 3 opposite strand (GATS), transcript variant 1, mRNA. 
chr7 99816871 99819111 PVRIG Homo sapiens poliovirus receptor related immunoglobulin domain containing (PVRIG), mRNA. 
chr7 99905324 99919819 SPDYE3 Homo sapiens speedy/RINGO cell cycle regulator family member E3 (SPDYE3), mRNA. 
chr7 99917162 99917190 DQ601342 Homo sapiens piRNA piR-59725, complete sequence. 
chr7 99918262 99933930 PMS2P1 Homo sapiens postmeiotic segregation increased 2 pseudogene 1 (PMS2P1), non-coding RNA. 
chr7 99927418 99930239 PMS2P1 Homo sapiens postmeiotic segregation increased 2 pseudogene 1 (PMS2P1), non-coding RNA. 
chr7 99933766 99949523 PILRB Homo sapiens paired immunoglobin-like type 2 receptor beta (PILRB), transcript variant 2, non-coding RNA. 
chr7 99955625 99965454 PILRB Homo sapiens paired immunoglobin-like type 2 receptor beta (PILRB), transcript variant 3, mRNA. 
chr7 99971067 99997722 PILRA Homo sapiens paired immunoglobin-like type 2 receptor alpha (PILRA), transcript variant 1, mRNA. 
chr7 99998494 100026431 ZCWPW1 Homo sapiens zinc finger, CW type with PWWP domain 1 (ZCWPW1), transcript variant 1, mRNA. 
chr7 100027253 100031749 MEPCE Homo sapiens methylphosphate capping enzyme (MEPCE), transcript variant 1, mRNA. 
chr7 100032911 100034094 PPP1R35 Homo sapiens protein phosphatase 1, regulatory subunit 35 (PPP1R35), mRNA. 
chr7 100054237 100061894 C7orf61 Homo sapiens chromosome 7 open reading frame 61 (C7orf61), mRNA. 
chr7 100064141 100076902 TSC22D4 Homo sapiens TSC22 domain family, member 4 (TSC22D4), mRNA. 
chr7 100081549 100092424 NYAP1 Homo sapiens neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 1 (NYAP1), mRNA. 
chr7 100136833 100165843 AGFG2 Homo sapiens ArfGAP with FG repeats 2 (AGFG2), mRNA. 
chr7 100169852 100171270 SAP25 Homo sapiens Sin3A-associated protein, 25kDa (SAP25), mRNA. 
chr7 100171633 100183776 LRCH4 Homo sapiens leucine-rich repeats and calponin homology (CH) domain containing 4 (LRCH4), mRNA. 
chr7 100187023 100201661 PCOLCE-AS1 Homo sapiens PCOLCE antisense RNA 1 (PCOLCE-AS1), non-coding RNA. 
chr7 100187195 100198740 FBXO24 Homo sapiens F-box protein 24 (FBXO24), transcript variant 3, mRNA. 
chr7 100199881 100205798 PCOLCE Homo sapiens procollagen C-endopeptidase enhancer (PCOLCE), mRNA. 
chr7 100210113 100213000 MOSPD3 Homo sapiens motile sperm domain containing 3 (MOSPD3), transcript variant 1, mRNA. 
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chr7 100218038 100239201 TFR2 Homo sapiens transferrin receptor 2 (TFR2), transcript variant 1, mRNA. 
chr7 100240725 100254084 ACTL6B Homo sapiens actin-like 6B (ACTL6B), mRNA. 
chr7 100254183 100264332 AK055267 Homo sapiens cDNA FLJ30705 fis, clone FCBBF2001116. 
chr7 100271362 100276792 GNB2 Homo sapiens guanine nucleotide binding protein (G protein), beta polypeptide 2 (GNB2), mRNA. 
chr7 100277129 100286870 GIGYF1 Homo sapiens GRB10 interacting GYF protein 1 (GIGYF1), mRNA. 
chr7 100303675 100305123 POP7 Homo sapiens processing of precursor 7, ribonuclease P/MRP subunit (S. cerevisiae) (POP7), mRNA. 
chr7 100318422 100321323 EPO Homo sapiens erythropoietin (EPO), mRNA. 
chr7 100331248 100395419 ZAN Homo sapiens zonadhesin (ZAN), transcript variant 6, mRNA. 
chr7 100400186 100425143 EPHB4 Homo sapiens EPH receptor B4 (EPHB4), mRNA. 
chr7 100450340 100464634 SLC12A9 Homo sapiens solute carrier family 12 (potassium/chloride transporters), member 9 (SLC12A9), transcript variant 1, mRNA. 
chr7 100464949 100471076 TRIP6 Homo sapiens thyroid hormone receptor interactor 6 (TRIP6), mRNA. 
chr7 100472700 100486285 SRRT Homo sapiens serrate RNA effector molecule homolog (Arabidopsis) (SRRT), transcript variant 1, mRNA. 
chr7 100486343 100487339 UFSP1 Homo sapiens UFM1-specific peptidase 1 (non-functional) (UFSP1), mRNA. 
chr7 100487614 100493541 ACHE Homo sapiens acetylcholinesterase (ACHE), transcript variant E4-E5, mRNA. 
chr7 100488709 100488760 DJ051769 Sequence 22 from Patent WO0136627. 
chr7 100550749 100611111 MUC3A SubName: Full=Mucin-3A; Flags: Fragment; 
chr7 100606877 100611410 AK096803 Homo sapiens cDNA FLJ39484 fis, clone PROST2014925. 
chr7 100612903 100662230 MUC12 Homo sapiens mucin 12, cell surface associated (MUC12), mRNA. 
chr7 100663363 100702140 MUC17 Homo sapiens mucin 17, cell surface associated (MUC17), mRNA. 
chr7 100728785 100733889 TRIM56 Homo sapiens tripartite motif containing 56 (TRIM56), mRNA. 
chr7 100770369 100782547 SERPINE1 Homo sapiens serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1), mRNA. 
chr7 100797685 100804557 AP1S1 Homo sapiens adaptor-related protein complex 1, sigma 1 subunit (AP1S1), mRNA. 
chr7 100802753 100802836 MIR4653 Homo sapiens microRNA 4653 (MIR4653), microRNA. 
chr7 100805789 100808852 VGF Homo sapiens VGF nerve growth factor inducible (VGF), mRNA. 
chr7 100813773 100823557 NAT16 Homo sapiens N-acetyltransferase 16 (GCN5-related, putative) (NAT16), mRNA. 
chr7 100839012 100844302 MOGAT3 Homo sapiens monoacylglycerol O-acyltransferase 3 (MOGAT3), mRNA. 
chr7 100849257 100861011 PLOD3 Homo sapiens procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3), mRNA. 
chr7 100860984 100867471 ZNHIT1 Homo sapiens zinc finger, HIT-type containing 1 (ZNHIT1), mRNA. 
chr7 100875372 100881227 CLDN15 Homo sapiens claudin 15 (CLDN15), transcript variant 2, mRNA. 
chr7 100882892 100888371 FIS1 
Homo sapiens fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) (FIS1), nuclear gene encoding mitochondrial protein, 
mRNA. 
chr7 100888045 100888132 Mir_324 Rfam model RF01063 hit found at contig region AC006329.5/14125-14039 
chr7 100893615 100895601 AK091729 Homo sapiens cDNA FLJ34410 fis, clone HEART2002129. 
chr7 100951620 100954265 BC032716 Homo sapiens cDNA clone IMAGE:5518697, **** WARNING: chimeric clone ****. 
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chr7 100956647 100965093 RABL5 Homo sapiens RAB, member RAS oncogene family-like 5 (RABL5), transcript variant 1, mRNA. 
chr7 100958773 100965093 RABL5 Homo sapiens RAB, member RAS oncogene family-like 5 (RABL5), transcript variant 2, mRNA. 
chr7 101006121 101202304 COL26A1 Homo sapiens collagen, type XXVI, alpha 1 (COL26A1), mRNA. 
chr7 101208596 101212286 BC027906 Homo sapiens clone 25248 mRNA sequence. 
chr7 101256604 101272576 MYL10 Homo sapiens myosin, light chain 10, regulatory (MYL10), mRNA. 
chr7 101460881 101901513 CUX1 Homo sapiens cut-like homeobox 1 (CUX1), transcript variant 1, mRNA. 
chr7 101928404 101962178 SH2B2 Homo sapiens SH2B adaptor protein 2 (SH2B2), mRNA. 
chr7 101936368 101936453 MIR4285 Homo sapiens microRNA 4285 (MIR4285), microRNA. 
chr7 101979403 101979439 DQ595418 Homo sapiens piRNA piR-45129, complete sequence. 
chr7 101986191 101996889 SPDYE6 Homo sapiens speedy/RINGO cell cycle regulator family member E6 (SPDYE6), mRNA. 
chr7 101989114 101989142 DQ601342 Homo sapiens piRNA piR-59725, complete sequence. 
chr7 102036803 102067129 PRKRIP1 Homo sapiens PRKR interacting protein 1 (IL11 inducible) (PRKRIP1), mRNA. 
chr7 102063377 102067120 AK097289 Homo sapiens cDNA FLJ39970 fis, clone SPLEN2027995. 
chr7 102073976 102097268 ORAI2 Homo sapiens ORAI calcium release-activated calcium modulator 2 (ORAI2), transcript variant 2, mRNA. 
chr7 102096666 102105321 ALKBH4 Homo sapiens alkB, alkylation repair homolog 4 (E. coli) (ALKBH4), mRNA. 
chr7 102105389 102113612 LRWD1 Homo sapiens leucine-rich repeats and WD repeat domain containing 1 (LRWD1), mRNA. 
chr7 102106188 102106273 MIR5090 Homo sapiens microRNA 5090 (MIR5090), microRNA. 
chr7 102111915 102111978 MIR4467 Homo sapiens microRNA 4467 (MIR4467), microRNA. 
chr7 102113547 102119381 POLR2J Homo sapiens polymerase (RNA) II (DNA directed) polypeptide J, 13.3kDa (POLR2J), mRNA. 
chr7 102123585 102158224 RASA4B Homo sapiens RAS p21 protein activator 4B (RASA4B), mRNA. 
chr7 102133833 102135811 AK311374 Homo sapiens cDNA, FLJ18416. 
chr7 102178365 102184517 POLR2J3 Homo sapiens polymerase (RNA) II (DNA directed) polypeptide J3 (POLR2J3), mRNA. 
chr7 102178365 102213068 POLR2J3 Homo sapiens polymerase (RNA) II (DNA directed) polypeptide J3 (POLR2J3), mRNA. 
chr7 102188513 102189359 BC041025 Homo sapiens cDNA clone IMAGE:3959993. 
chr7 102191678 102202757 SPDYE2B Homo sapiens speedy/RINGO cell cycle regulator family member E2B (SPDYE2B), mRNA. 
chr7 102201021 102201049 DQ601342 Homo sapiens piRNA piR-59725, complete sequence. 
chr7 102220092 102257205 RASA4 Homo sapiens RAS p21 protein activator 4 (RASA4), transcript variant 1, mRNA. 
chr7 102233002 102234980 AK311374 Homo sapiens cDNA, FLJ18416. 
chr7 102277194 102283238 POLR2J2 Homo sapiens polymerase (RNA) II (DNA directed) polypeptide J2 (POLR2J2), mRNA. 
chr7 102277194 102312176 POLR2J2 Homo sapiens polymerase (RNA) II (DNA directed) polypeptide J2 (POLR2J2), mRNA. 
chr7 102287607 102288458 BC041025 Homo sapiens cDNA clone IMAGE:3959993. 
chr7 102290771 102301847 SPDYE2B Homo sapiens speedy/RINGO cell cycle regulator family member E2B (SPDYE2B), mRNA. 
chr7 102300111 102300139 DQ601342 Homo sapiens piRNA piR-59725, complete sequence. 
chr7 102321131 102328837 AK301666 SubName: Full=cDNA FLJ50902, moderately similar to Ras GTPase-activating protein 4; 
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chr7 102389398 102449672 FAM185A Homo sapiens family with sequence similarity 185, member A (FAM185A), transcript variant 1, mRNA. 
chr7 102453307 102715015 FBXL13 Homo sapiens F-box and leucine-rich repeat protein 13 (FBXL13), transcript variant 1, mRNA. 
chr7 102553343 102585556 LRRC17 Homo sapiens leucine rich repeat containing 17 (LRRC17), transcript variant 1, mRNA. 
chr7 102715327 102740210 ARMC10 Homo sapiens armadillo repeat containing 10 (ARMC10), transcript variant A, mRNA. 
chr7 102740022 102789569 NAPEPLD Homo sapiens N-acyl phosphatidylethanolamine phospholipase D (NAPEPLD), transcript variant 1, mRNA. 
chr7 102781716 102782850 RPL19P12 Homo sapiens ribosomal protein L19 pseudogene 12 (RPL19P12), non-coding RNA. 
chr7 102815461 102920759 DPY19L2P2 Homo sapiens dpy-19-like 2 pseudogene 2 (C. elegans) (DPY19L2P2), transcript variant 2, non-coding RNA. 
chr7 102913538 102920913 DPY19L2P2 Homo sapiens dpy-19-like 2 pseudogene 2 (C. elegans) (DPY19L2P2), transcript variant 1, non-coding RNA. 
chr7 102937872 102955133 PMPCB Homo sapiens peptidase (mitochondrial processing) beta (PMPCB), nuclear gene encoding mitochondrial protein, mRNA. 
chr7 102952920 102985320 DNAJC2 Homo sapiens DnaJ (Hsp40) homolog, subfamily C, member 2 (DNAJC2), transcript variant 1, mRNA. 
chr7 102987970 103009842 PSMC2 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 2 (PSMC2), transcript variant 1, mRNA. 
chr7 103014654 103086624 SLC26A5 Homo sapiens solute carrier family 26, member 5 (prestin) (SLC26A5), transcript variant a, mRNA. 
chr7 103075440 103075539 Y_RNA Rfam model RF00019 hit found at contig region AC005064.3/33168-33070 
chr7 103112230 103629963 RELN Homo sapiens reelin (RELN), transcript variant 2, mRNA. 
chr7 103124654 103124986 7SK Rfam model RF00100 hit found at contig region AC005064.3/82615-82284 
chr7 103766787 103848495 ORC5 Homo sapiens origin recognition complex, subunit 5 (ORC5), transcript variant 1, mRNA. 
chr7 103969103 104549003 LHFPL3 Homo sapiens lipoma HMGIC fusion partner-like 3 (LHFPL3), mRNA. 
chr7 103969740 103969760 JB175200 Oligonucleotides for modulating target RNA activity. 
chr7 104439446 104444539 LHFPL3-AS1 Homo sapiens LHFPL3 antisense RNA 1 (LHFPL3-AS1), transcript variant 1, non-coding RNA. 
chr7 104535074 104567092 LHFPL3-AS2 Homo sapiens LHFPL3 antisense RNA 2 (LHFPL3-AS2), non-coding RNA. 
chr7 104581652 104602781 BC061919 Homo sapiens cDNA clone IMAGE:4358995, partial cds. 
chr7 104622193 104631612 LOC100216546 Homo sapiens uncharacterized LOC100216546 (LOC100216546), non-coding RNA. 
chr7 104650988 104654588 LOC100216545 Homo sapiens uncharacterized LOC100216545 (LOC100216545), non-coding RNA. 
chr7 104654636 104754532 KMT2E Homo sapiens lysine (K)-specific methyltransferase 2E (KMT2E), transcript variant 1, mRNA. 
chr7 104748533 104749020 AF520793 Homo sapiens chromosome 7 unknown mRNA. 
chr7 104754024 104754437 AF520792 Homo sapiens clone IMAGE: 252897 mRNA sequence. 
chr7 104754466 104755465 AF520792 Homo sapiens clone IMAGE: 252897 mRNA sequence. 
chr7 104756820 105029377 SRPK2 Homo sapiens SRSF protein kinase 2 (SRPK2), transcript variant 1, mRNA. 
chr7 105096959 105162685 PUS7 Homo sapiens pseudouridylate synthase 7 homolog (S. cerevisiae) (PUS7), mRNA. 
chr7 105172531 105208124 RINT1 Homo sapiens RAD50 interactor 1 (RINT1), mRNA. 
chr7 105206771 105221976 EFCAB10 Homo sapiens EF-hand calcium binding domain 10 (EFCAB10), non-coding RNA. 
chr7 105208141 105208836 BC007100 Homo sapiens cDNA clone IMAGE:4279216, **** WARNING: chimeric clone ****. 
chr7 105245220 105517031 ATXN7L1 Homo sapiens ataxin 7-like 1 (ATXN7L1), transcript variant 1, mRNA. 
chr7 105603656 105676877 CDHR3 Homo sapiens cadherin-related family member 3 (CDHR3), mRNA. 
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chr7 105730813 105753093 SYPL1 Homo sapiens synaptophysin-like 1 (SYPL1), transcript variant 1, mRNA. 
chr7 105848612 105848713 U6 Rfam model RF00026 hit found at contig region AC007032.2/13823-13923 
chr7 105888731 105925638 NAMPT Homo sapiens nicotinamide phosphoribosyltransferase (NAMPT), mRNA. 
chr7 106130171 106410653 AF086203 Homo sapiens full length insert cDNA clone ZC44D09. 
chr7 106297210 106301634 CCDC71L Homo sapiens coiled-coil domain containing 71-like (CCDC71L), mRNA. 
chr7 106505923 106547592 PIK3CG Homo sapiens phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma (PIK3CG), mRNA. 
chr7 106685177 106802256 PRKAR2B Homo sapiens protein kinase, cAMP-dependent, regulatory, type II, beta (PRKAR2B), mRNA. 
chr7 106809405 106842974 HBP1 Homo sapiens HMG-box transcription factor 1 (HBP1), transcript variant 1, mRNA. 
chr7 106842188 107204959 COG5 Homo sapiens component of oligomeric golgi complex 5 (COG5), transcript variant 1, mRNA. 
chr7 107110501 107116125 GPR22 Homo sapiens G protein-coupled receptor 22 (GPR22), mRNA. 
chr7 107204401 107218968 DUS4L Homo sapiens dihydrouridine synthase 4-like (S. cerevisiae) (DUS4L), transcript variant 2, mRNA. 
chr7 107221203 107263762 BCAP29 Homo sapiens B-cell receptor-associated protein 29 (BCAP29), transcript variant 1, mRNA. 
chr7 107243807 107243952 SnoU109 Rfam model RF01233 hit found at contig region AC004839.1/36528-36672 
chr7 107296960 107302243 SLC26A4-AS1 Homo sapiens SLC26A4 antisense RNA 1 (SLC26A4-AS1), non-coding RNA. 
chr7 107301079 107358252 SLC26A4 Homo sapiens solute carrier family 26, member 4 (SLC26A4), mRNA. 
chr7 107312769 107312855 Mir_548 Rfam model RF01061 hit found at contig region AC078937.1/49798-49713 
chr7 107384278 107402083 CBLL1 Homo sapiens Cbl proto-oncogene, E3 ubiquitin protein ligase-like 1 (CBLL1), transcript variant 1, mRNA. 
chr7 107405911 107443678 SLC26A3 Homo sapiens solute carrier family 26, member 3 (SLC26A3), mRNA. 
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Supplementary Table 3. Translational start predictions. 
Position Score Prediction Kozak consensus 
gccRccAUGG 
P1 transcript 
   uAUG 115 0.549 yes cccGggAUGA 
AUG1 182 0.729 yes gcgGagAUGG 
AUG2 196 0.644 yes gcaCgaAUGT 
P2 long transcript 
  AUG1* 58 0.263 no aagTggAUGC 
AUG2* 103 0.416 no gatTgaAUGA 
AUG3* 137 0.482 no gctTgcAUGG 
AUG4* 180 0.351 no gtgGggAUGA 
AUG2 254 0.656 yes gcaCgaAUGT 
 P2 short transcript 
AUG1* 58 0.314 no aagTggAUGC 
AUG2 65 0.512 yes gcaCgaAUGT 
NetStart 1.0 prediction server 15 has been used to calculate the robustness of 
different AUGs to initiate the translation in the P1, P2 and P2 short transcripts. 
Score greater than 0.5 represent a probable translation start.  
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Supplementary Table 4. Primer list. 
EPO exon 2 sequencing primer sequence 5'->3' 
EPO exon 2 fwd GCCACCACTTATCTGCCA 
EPO exon 2 rev AACTCCACCCCAAACCAA 
Microsatellite mapping primer sequence 5'->3' 
D7S669 (q21.11) FAM-ATGCAACCTACCCTCAAATG 
gtttcTACGGGTTACCCACATTGCTAT 
D7S630 FAM-TCCATTCTGAGGTTTGATGT 
gtttcCCATGGTCTTTTCAATGAAC 
D7S657 FAM-GGAATCTGGTAGACTGGTTT 
gtttcCCCTGCCTCTAAAATTATAC 
D7S1812 FAM-GGAGGAAGGTGGATAATAATAGG 
gtttcAATGTCACAAGGGTGCAGAT 
D7S554 FAM-GTCTAATTACCCACATTTCCCT 
gtttcGTTCCATATTTAAAAGACTCAGTGA 
D7S666 FAM-GCCTTCTCAAGCAAATTGAT 
gtttcCCTGATATGTGAGGTAATGAAAGAG 
D7S2504 FAM-TGTGGTACAATTTCAGACACATAA 
gtttcCTGGAAACCAGTGTTTTCACTT 
D7S2459 FAM-AAGAAGTGCATTGAGACTCC 
gtttcCCGCCTTAGTAAAACCC 
D7S486 FAM-AAAGGCCAATGGTATATCCC 
gtttcGCCCAGGTGATTGATAGTGC 
D7S530 (q32.2) FAM-TGCATTTTAGTGGAGCACAG 
gtttcCAGGCATTGGGAACTTTG 
CRISPR sgRNA cloning primer sequence 5'->3' 
sgRNA #2 CACCGTCCCTGCTGTCGCTCCCTCT 
TCCCTGCTGTCGCTCCCTCT AAACAGAGGGAGCGACAGCAGGGAC 
 SNP TaqMan genotyping 
primers primer sequence 5'->3' 
hEPO ΔG SNP genotyping fwd TATCTGTTCTAGAATGTCCTGCCT 
hEPO ΔG SNP genotyping rev GGAGCGACAGCAGGGA 
TaqMan probe WT (VIC-NFQ) CAGGAGAAGCCACAGCC 
TaqMan probe MUT (FAM-NFQ) CAGGAGAAGCACAGCC 
GSP primers for 5'RACE primer sequence 5'->3' 
GSP1 GATTACGCCAAGCTTAGCAGTGATTGTTCGGAGTGGAGCAG 
GSP2 GATTACGCCAAGCTTAGAGCCCGAAGCAGAGTGGTGAGGC 
EPO transcripts quantitation primer sequence 5'->3' 
EPO P1 fwd CGGCCAGGCGCGGAGATG 
EPO P2 long fwd CTGACTCTCAGCCTGGCTAT 
EPO P2 short fwd TGGATGCTGAATGTCCTGC 
EPO rev (exon 3-4 boundary) GCTGCAGTGTTCAGCACAGC 
GUSB fwd ATCGCCATCAACAACACACT 
GUSB rev TGGGATACTTGGAGGTGTCA 
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Cloning of EPO expression 
constructs and site-directed 
mutagenesis primer sequence 5'->3' 
EPO P1 fwd GCAAAAGCTTTTCCCGGGATGAGGGCC 
EPO rev GCAAGAATTCAGGGAGGTGGTGGATATG 
EPO exon 2 rev GCAAGGTACCTCTCCAGGACTCGGCT 
hEPO P1 ΔUTR fwd GCAAAAGCTTGGCGCGGAGATGGGGGTG 
hEPO P2 ΔUTR fwd GCAAAAGCTTTCTCAGCCTGGCTATCTGTT 
hEPO ΔG mutagenesis fwd GAATGTCCTGCCTGGCTGTGCTTCTCCTG 
hEPO ΔG mutagenesis rev CAGGAGAAGCACAGCCAGGCAGGACATTC 
hEPO ΔC mutagenesis fwd GGGTGCACGAATGTCTGCCTGGCTGTGG 
hEPO ΔC mutagenesis rev CCACAGCCAGGCAGACATTCGTGCACCC 
CRISPR off-target analysis primer sequence 5'->3' 
CRISPR OT1 TGGATGGGCGTTATTGTTGT 
GGCTGGGAGAAGGGAGGA 
CRISPR OT2 GATTAGACAGGAAGTGGGG 
TGCAGTGAGCTACGATGG 
CRISPR OT3 GAAGGTGAGAAGAGAAGG 
AAATAGAAGACAGGGAGG 
CRISPR OT4 CCTCGTTCCTGTTAACTCT 
CACACTCCCTTCAAATCC 
CRISPR OT5 CCTCTTCTCACTTTTTATCTTC 
CTCGAGAGTCCTATATTTTG 
CRISPR OT6 TTTTTCTTTATTCCCAACTCC 
GCTTCCCACTATTTTTTTTCA 
CRISPR OT7 TTTGTTTCTTCACCTGGC 
TCTTCATCCTTTCCCCTC 
CRISPR OT8 CCTTCCCTCCAACATCCT 
TCTGTCATCCCACCACTT 
CRISPR OT9 TGTGTGTATGTGTGTGTG 
ACAATTGGGGGAAAAAAAAC 
CRISPR OT10 CCAGCCGTTAATATTTGT 
TCTCGTTTTTCTTTGTCTT 
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Supplementary Table 5. CRISPR off-target detection. 
Tool	 ID	 Sequence	 Type	 Mismatch	 Location	 Strand	
ZHANG	
score	 COSMID	score	 GENE	
 TCCCTGCTGTCGCTCCCTCTGGG Target	 0	 Chr7:	100319209	 +	 	NM_000799	
TOP	5	PREDICTED	OFF-TARGETS	MIT/ZHANG	ALGORHITM	
ZHANG	 OT1	  TCCCCGCCCTCGCTCCCTCTTGG No	indel	 3	 Chr6:	167529802	 +	 1,48 intronic	CCR6	(NM_004367)	
ZHANG	 OT2	  CCCCTGCCGTCCCTCCCTCTCAG No	indel	 3	 Chr19:	33639182	 +	 1,42 intronic	WDR88	(NM_173749)	
ZHANG	 OT3	  ACCCTGCCGTCTCTCCCTCTGGG No	indel	 3	 Chr19:	47920846	 - 1,42
intronic	MEIS3	
(NM_001009813)	
ZHANG	 OT4	  TTCCTGCAGTCACTCCCTCTGGG No	indel	 3	 Chr11:	67038150	 + 1,38 intronic	ADRBK1	(NM_001619)	
ZHANG	 OT5	  CCAATGCCGTCGCTCCCTCTGAG No	indel	 4	 Chr4:	96727670	 - 1,37 intergenic	
TOP	5	PREDICTED	OFF-TARGETS	COSMID	ALGORHITM	
COSMID	 OT6	  TCCCTGCTGTCCTTCCCTCTGGG No	indel	 2	 Chr4:1080908	 -	 1,9	 intronic	RNF212	(NM_194439)	
COSMID	 OT7	  TCCCTG-TGTTGCTCCCTCTAGG Del	14	 1	 Chr1:237060285	 +	 1,44	 intronic	MTR	(NM_000254)	
COSMID	 OT8	  TCCCTCCT-TCGCTCCCTCTGGG Del	12	 1	 Chr12:66275392	 -	 1,07	 intronic	HMGA2	(NM_003484)	
COSMID	 OT9	  TCCCTGCTCT-GCTCCCTCTAGG Del	10	 1	 Chr19:43421026	 +	 1,56	 intronic	PSG6	(NM_021016)	
COSMID	 OT10	  TCCCAGCTGTC-CTCCCTCTAGG Del		9	 1	 Chr19:9169775	 +	 1,5	 intergenic	
List of the top five off-target sites predicted for the sgRNA used for CRISPR-mediated editing of exon 2 of the EPO gene by the Zhang laboratory 
algorithm (crispr.mit.edu) and the COSMID tool 3 (crispr.bme.gatech.edu). Red nucleotides indicate sequence differences from the target sequence. 
PCR amplification of the target loci followed by Sanger sequencing did not identify any off-target modifications.  
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ABSTRACT 
 
Hereditary thrombocytosis, a myeloproliferative disorder is characterized by the elevated 
platelet counts. Mutations in the MPL and JAK2 genes are responsible for the primary 
thrombocytosis associated with low serum thrombopoietin (TPO) levels. Thrombopoietin 
(THPO) mutations cause secondary thrombocytosis characterized by increased TPO levels. 
We studied a pedigree with autosomal-dominant thrombocytosis and identified a novel 
activating mutation in exon 3 of the THPO gene. This mutation, a single nucleotide 
substitution G>T, is located within the Kozak sequence of the upstream open reading 
frame 7 (uORF7), the most critical negative regulator of THPO translation.  We performed 
TPO overexpression and in vitro translation experiments to show that the G>T mutation 
disrupts the negative regulation governed by uORF7 and allows for increased translation of 
THPO protein coding sequence, ultimately causing thrombocytosis.   
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INTRODUCTION 
 
Hereditary thrombocytosis also called congenital thrombocythemia is a myeloproliferative 
syndrome transmitted by an autosomal dominant mode of inheritance with the prevalence 
of < 1:100,000 in the general population.1 It is classified by the increase in the number of 
thrombocytes above 450x109/L for the period over six months.1,2 Based on the platelet 
counts, thrombocytosis may be classified as mild (450-700 x109/L), moderate (700-900 
x109/L) or severe (>900 x109/L). 2 
Familial thrombocytosis can be classified as primary when the defect is intrinsic to the 
megakaryocyte progenitors in the bone marrow. Mutations in the genes involved in the 
thrombopoietin (TPO) signaling pathway (MPL3-7 and JAK28,9) lead to the TPO-
independent signaling. Primary thrombocytosis is therefore accompanied by low TPO 
serum levels.  Secondary thrombocytosis is caused by the mutations in the thrombopoietin 
(THPO) gene itself and is characterized by high TPO serum levels.  So far, three different 
mutations (ΔE3, c.ΔG500, and c.G516T) in the THPO gene have been reported as a cause 
of hereditary thrombocythemia. 10-19 
THPO expression is regulated on the translational level by seven upstream open reading 
frames (uORF1-7) in the exons 1-3 of THPO mRNA, that are interfering with the 
translation of TPO. 20,21 uORF7 extends beyond the AUG initiating the translation of 
THPO mRNA, thus being the most critical negative regulator. All previously reported 
mutations in the THPO gene associated with hereditary erythrocytosis also destroy the 
negative regulation governed by uORF7. 22 
Here we report a pedigree diagnosed with thrombocytosis having a novel activating 
mutation in the THPO gene. G>T transversion weakens the Kozak consensus sequence 
of uORF7, thereby decreasing the translation rate of this open reading frame, which 
conversely allows for the increased translation of the TPO protein, leading to the 
thrombocytosis in the studied family. 
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METHODS 
 
Study family and patient samples 
The study was approved by the … and by Ethikkommission Beider Basel, Switzerland. All 
participating family members provided written informed consent to participate in the study. 
Measurements of hemoglobin, leukocytes, and platelets were carried out at the … during 
the time period of …. 
 
THPO gene sequence analysis 
Primers flanking exon 3 of human THPO (fwd: 5'-TGCCAGGCAGTCTCTTCC-3', rev: 5'- 
CTGCAGCGTGTCTCCTTTC-3') were used for PCR amplification with Q5 High-Fidelity 
DNA Polymerase (NEB). PCR products were purified with Exonuclease I and 
Thermosensitive Alkaline Phosphatase mix (Thermo Fisher) by incubating 15min. at 37°C 
followed by 85°C for 15min. Reactions were submitted for Sanger sequencing to 
Microsynth. Sequences were analyzed with CLC Main Workbench 7.7.1 (Qiagen).  
  
Cell lines and transfections 
HEK293LTV cell line (Cell Biolabs) was maintained in high glucose DMEM with L-
glutamine supplemented with 10% fetal bovine serum (Sigma) and Penicillin/Streptomycin 
mix (GIBCO Invitrogen). For overexpression experiments, 2,5x105 of HEK293LTV cells 
per well (6-well plates) were transfected with 0.5 µg of the plasmid using jetPRIME 
reagent (Polyplus Transfection), and supernatants were harvested 72 hours post 
transfection. BaF3-hMPL cells (kindly provided by Dr. Sara C. Meyer) were cultured in 
RPMI media with L-glutamine, and HEPES (GIBCO Invitrogen) supplemented with 10% 
fetal bovine serum (Sigma), penicillin-Streptomycin mix (GIBCO Invitrogen) and 5ng/ml 
recombinant murine IL-3 (Peprotech). Cells were grown at 37 °C in 5 % CO2 humidified 
atmosphere with 21% O2. 
 
THPO expression constructs 
THPO expression constructs were prepared as described previously. 11,13 All constructs 
were sub-cloned into the pcDNA3 expression vector (Invitrogen). For introducing the 
G480T mutation into the plasmid, QuickChange Lightning Multi Site-Directed 
Mutagenesis Kit (Agilent Technologies) was used with the forward 5-
GCCGCCTCCATGTCCCCAGGAAGGA-3' and reverse 5'-
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TCCTTCCTGGGGACATGGAGGCGGC-3' primers. Plasmid sequences were verified 
with Sanger sequencing (Microsynth), and midiprep DNA was produced with NucleoBond 
Xtra Midi kit (Macherey-Nagel). 
 
TPO levels measurement  
Cell supernatants from transfected HEK293LTV cells were sterile-filtered (0.22µm), and 
TPO levels were measured with human Human Tpo Quantikine Immunoassay (R&D 
Systems), and absorbance was measured was measured on Synergy H1 microplate reader 
(Biotek) equipped with Gen5 v2.05 software.   
 
Proliferation assay 
Cell proliferation rates were measured by using CellTiter-Glo Luminescent Cell Viability 
Assay (Promega). Supernatants from transfected HEK293LTV cells were used to stimulate 
the growth of BaF3-hMPL cell line. Recombinant human TPO (Peprotech) was used as a 
positive control. BaF3-hMPL cells were washed three times with PBS, and 5x103 cells per 
well were plated into 96-well plates and incubated in RPMI + 10% FBS with the 10-fold 
dilution of cell supernatants or recombinant human TPO for 72 hours. Then, 30 µl of cells 
were transferred into black opaque 96-well plates (Eppendorf) and incubated with equal 
volume of Cell-Titer-Glo Reagent according to the manufacturer's protocol. Luminescence 
was measured on Synergy H1 microplate reader (Biotek) equipped with Gen5 v2.05 
software.   
 
In vitro transcription and translation 
THPO constructs in pcDNA3 vector were linearized with XbaI, extracted with phenol-
chloroform and ethanol-precipitated. 1µg of linearized DNA was used as a template for 
in vitro transcription using T7 MEGAScript kit (Thermo Fisher Scientific). Reactions 
were incubated for 4 hrs at 37°C, followed by DNase treatment and phenol-chloroform 
extraction. The identity of the different THPO transcripts was verified by Agilent 2100 
Bioanalyzer. 1.5ug of each THPO mRNA was translated for 2 hrs at 25°C using a wheat 
germ extract lysate (Promega) in the presence of FluoroTect Green in vitro Translation 
Labeling System (Promega). Labeled proteins were separated on NuPAGE 12% Bis-
Tris Protein gels (Invitrogen) and visualized on Typhoon 9400 Imaging System (GE 
Healthcare Life Sciences) using 488nm laser and 526SP emission filter. Quantification 
of the amount of translated protein by densitometry was performed with Image Studio 
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Lite 5.2.5 (LI-COR Biosciences). 
Statistical analysis 
Statistical significance of the data was tested with one-way ANOVA or two-way ANOVA 
and analyzed using GraphPad Prism 7 software, P values are provided.  
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RESULTS 
 
We studied the Dutch pedigree diagnosed with mild thrombocytosis (Figure 1A). Affected 
family members displayed elevated thrombocyte counts > 450 x109/L (Figure 1A and 
Figure 1B). Serum TPO levels stayed within the normal range of 4-31 ??/?? (Figure 1B). 
Sequence analysis of the THPO gene shown in Figure 1C revealed a heterozygous G>T 
transversion in the exon 3 (chr3: 184,094,114 G>T). This mutation, c.G480T was present 
in all affected family members and also in one family member without thrombocytosis 
(EN05). G480T transversion appears at the position +4 of uAUG7, which is an essential 
part of a Kozak consensus sequence 23 (Figure 1C). In line with this observation, 
translational start site score has decreased from 0.693 to 0.646 upon the introduction of the 
mutation, as predicted by NetStart 1.0 prediction server. 24 
We, therefore, hypothesized that G480T mutation decreases the translation initiation from 
uAUG7 and allows for the increased translation of THPO protein coding sequence. To test 
this, we cloned cDNAs coding for wildtype THPO, THPO with G480T mutation or other 
reported mutations (G516T, ΔG500, and ΔE3) into pcDNA3 vector (Figure 2A). These 
constructs represent the most abundant form of THPO mRNA that constitutes ~ 90% of 
THPO mRNAs, and uORF5 is the first ORF translated.20 To assess the contribution of 
uORF7 only, we have also prepared and tested short, artificial constructs that begin with 
uORF7 (Supplementary Figure 1A). 
Next, we transfected HEK293 cells with these constructs and measured TPO protein in cell 
culture supernatants by ELISA. Cells transfected with cDNAs carrying G480T mutation 
produced more TPO than cells transfected with wildtype construct (Figure 2B and  
Supplementary Figure 1B). Also, cDNAs bearing G516T, ΔG500, and ΔE3 mutations 
produced more TPO than the wildtype cDNA. In comparison to other mutations, G480T 
showed the mildest increase in TPO levels. Supernatants from cells with wildtype cDNA 
or cDNA carrying G480T, G516T, ΔG500, and ΔE3 mutations also stimulated the growth 
of TPO-dependent BaF3-MPL cells in a concentration-dependent manner, demonstrating 
that THPO G480T produces biologically active TPO protein (Figure 2C and 
Supplementary Figure 1C). 
To directly prove that G480T increases the translational efficiency of THPO mRNA, we 
performed in vitro transcription-translation experiment. In vitro translation of the THPO 
G480T mRNA produced more TPO protein than the translation of THPO wildtype mRNA 
(Figure 2B and Supplementary Figure 1B). Also, in vitro translation of THPO G516T, 
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ΔG500 and ΔE3 mRNAs produced more TPO protein than THPO wildtype mRNA. In line 
with the previous reports, THPO mRNA with ΔE3 and ΔG500 mutations produced larger 
TPO molecules of ~ 41.1 kDa and ~ 40.3 kDa respectively as a result of initiation from 
upstream AUGs due to the in-frame fusion with uORF5 in case of ΔE3 and uORF7 in case 
of ΔG500 (Figure 2B and Supplementary Figure 1B). 
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DISCUSSION 
 
In this study, we described a novel activating mutation in the THPO gene leading to the 
hereditary thrombocytosis. This G>T transversion resides in the exon 3 of the THPO 
gene and is a part of the Kozak consensus sequence of uORF7, a negative regulator of 
THPO translation 25 (Figure 1C).  Mutations in the Kozak sequence have been 
previously reported to be involved in the disease pathogenesis of β-thalassemia 26, 
congenital heart defects 27, androgen insensitivity syndrome 28, ataxia 29, and breast 
cancer 30.  
We demonstrated that G480T mutation destroys the negative regulation of THPO 
translation employed by uORF7. G>T transversion occurs at the position +4 of the 
Kozak consensus sequence that is essential for efficient translational initiation. 23 As a 
result, translation initiation from uORF7 is decreased, which allows ribosomes to 
initiate the translation from AUG8, a start codon of TPO peptide.  
We showed that supernatant of HEK293 cells transfected with THPO G480T construct 
contains more TPO protein than supernatants transfected with THPO wildtype cDNA 
(Figure 2B and Supplementary Figure 1B). Cell culture supernatant is also biologically 
active as evidenced by the growth of TPO-dependent cell line (Figure 2C and 
Supplementary Figure 1C). Furthermore, G>T mutation translates into the milder 
phenotype than previously reported mutations (Figure 1). This observation can be 
explained by the fact that the guanine at +4 position is only one of the required residues 
of the Kozak consensus sequence. 23 In conclusion, a weak effect of G480T mutation we 
demonstrated in our molecular and cellular assays results in the mild thrombocytosis in 
the affected members of the pedigree.   
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FIGURE LEGENDS 
 
Figure 1. Pedigree with hereditary thrombocytosis and identification of the THPO 
mutation. A) Schematic drawing of the pedigree. Unique patient numbers are placed under 
the symbols, numbers below represent the highest recorded thrombocyte values (x109/L), 
and the THPO gene sequence status is indicated as wildtype (WT), or mutated (G>T). B) 
Thrombocyte (PLT) and serum thrombopoietin (TPO) levels are plotted for the individuals 
from the pedigree shown in 1A. The grey shaded area indicates the normal range of PLT 
levels in the blood and TPO levels in serum. C) Chromatograms showing the DNA 
sequences of the mutated locus. Nucleotide sequence on the top depicts Kozak consensus 
sequence, the most critical residues at positions -3 and +4 marked in bold, initiating AUG 
triplet is framed with the pink box. The heterozygous G>T transversion in affected family 
members is indicated with the red box. Numbers next to the chromatograms are scores 
calculated by NetStart 1.0 prediction server to estimate the robustness of different AUGs to 
initiate the translation. The score greater than 0.5 represents a probable translation start. 
 
Figure 2. Functional characterization of the THPO G>T mutation. A) Schematic drawing 
showing the translational reading frames of THPO  wildtype transcript (A) and the 
consequence of the different mutations on the initiation of TPO translation (B-E). Open 
reading frames (ORFs) are depicted with numbers, red-colored are upstream ORFs and 
blue-colored is ORF coding for TPO protein. B) Upper part: TPO protein concentration 
measured in culture supernatants from HEK293 cells transfected with cDNA constructs 
depicted in A. TPO protein was measured by TPO ELISA and TPO concentrations are 
given as mean ± SD (n=3), P values were determined by one-way ANOVA. Middle part: 
In vitro transcription-translation of  EPO mRNAs. Equal amounts of in vitro transcribed 
EPO mRNA variants (top) were used for in vitro translation in wheat germ lysates in the 
presence of fluorescently labeled lysine. TPO proteins separated by SDS-gel 
electrophoresis and visualized by fluorescent imager are shown in the bottom. The 
predicted molecular weight of wildtype TPO protein including signal peptide is 37.8 kDa. 
A higher molecular weight bands present in the lanes for ΔG500 (~ 40.3 kDa) and ΔE3 (~ 
41.1 kDa)  constructs represent TPO protein initiating from the upstream AUG7 that is in 
frame with the TPO reading frame and TPO protein initiating from the upstream AUG5, 
when exon 3 is skipped, respectively and are marked with an asterisk. Lower part: 
Densitometry of TPO protein from in vitro translation experiments, AU = arbitrary units. 
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C) The biological activity of TPO produced by transfected HEK293 cells with cDNA 
constructs depicted in A was measured in culture supernatants by a proliferation assay with 
BaF3-MPL cell line. Serial dilutions of 100ng/ml of recombinant human TPO were used 
for reference, n=3. 
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Supplementary Figure 1
Supplementary Figure 1. Functional characterization of the THPO G>T mutation with ΔuORF5 constructs.
A) Schematic drawing of THPO constructs lacking uORF5 analogous to the ones in Figure 2. B-C) TPO 
ELISA and in vitro transcription-translation (B), and proliferation assay (C) were performed with ΔuORF5 
constructs analogous to the Figure 2. Note that the results of the  ΔUTR construct, the empty vector and 
hTPO control shown for reference are taken from Figure 2C.
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2.3 Murine models to study MPN 		
2.3.1 Lineage bias of HSPC population 	
One of the crucial questions in the MPN field is how a single mutation in JAK2 (JAK2 
V617F) can cause clinically distinct diseases (PV, ET, and PMF). Recently, multiple 
reports described the heterogeneity of HSC compartment (Perié et al., 2015; 
Sanjuan-Pla et al., 2013; Yamamoto et al., 2013) with the possible bias towards a 
particular lineage, demonstrated for the megakaryocyte-biased HSCs (Grover et al., 
2016; Haas et al., 2015; Sanjuan-Pla et al., 2013). These HSCs are thought to 
predominantly give rise to a special type of progenitor, and mutational hit in such a 
stem cell could explain different phenotype outcomes. To investigate this in more 
detail, we plan to FACS sort "biased" stem cells with a combination of different cell 
surface markers, and to subsequently transplant them into lethally irradiated BL6 
recipients.  
Standard transplantation procedure in the lab involves transgene induction (SclCre; 
JAK2 V617F) in the donor mice followed by FACS sorting of pre-induced (mutated) 
cells and subsequent transplantation. The caveat of this setup is, however, that the 
expression pattern of some of the markers used for cell sorting may be changed 
upon JAK2 V617F activation (Lundberg et al., 2014). Moreover, unpublished results 
from our lab suggest, that whole bone marrow cell suspension is more effective in 
disease initiation than the population of sorted HSCs. This could have three possible 
explanations:  
 
1. cells in the bone marrow of non-hematopoietic origin are playing an active part in 
the disease initiation and progression. 
2. mechanical stress during FACS sorting damages LT-HSC and impair their 
proliferation capacity. 
3. FACS sorting of pre-induced HSC does not enrich for the correct cell population.  
 
To study the third possibility, we attempted to set-up a system allowing us to sort 
non-induced HSCs, and activate them afterward, either in vitro or in vivo. For the in 
vitro part, we isolated bone marrow cells from JAK2 V617F donor mice (Tiedt et al., 
2008) and FACS-sorted LT-HSC population (defined as Lin-, Sca-1+, c-kit+, CD150+, 
CD48- population).  Next, LT-HSCs were incubated with different concentrations of 
4-hydroxytamoxifen (4-OHT) to activate the transgene and plated on methyl- 
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Figure 13. Activation of LT-HSC by 4-OHT in vitro. A) Experimental setup describing the isolation of LT-HSC 
population (defined as Lin-, Sca-1+, c-kit+, CD150+, CD48- subset) and subsequent incubation with 4-OHT 
(Tam), either in direct culture (D) or with the pre-culture in Stemspan medium (P) for various time points. Cells 
were then plated on the methylcellulose plates, let to grow colonies, picked, DNA was isolated, and the 
number of activated transgene copies was assessed by qRT-PCR. B) The number of colonies grown from 
LT-HSCs incubated for different time points with varying concentrations of 4-OHT. C)  Percent of activated 
copies of the human JAK2 V617F transgene.   
 
 
 
 
An erythroblastic island. A) Immunohistology image of E13.5 mouse metal liver shows a central 
macrophage stained with the F4/80 antibody in brown surrounded by erythroid cells at various 
stages of differentiation. B) Schematic drawing of an erythroblastic island. Reticulocytes detach 
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cellulose plates to grow colonies (Figure 13A). Prior to the 4-OHT exposure, cells 
were either preincubated for 16 hours in Stemspan (P), or directly sorted into the 
Stemspan with 4-OHT (D). We hypothesized that pre-culture in Stemspan might 
help LT-HSCs to enter the cell cycle and be more accessible for Cre-mediated 
recombination. Afterward, DNA was isolated from colonies and subjected to the 
qRT-PCR to assess the number of activated transgene copies in single colonies.  
Colony counting showed, that both high concentrations of 4-OHT (750nM) and 
prolonged incubation times had a negative impact on the colony survival. 
Conversely, pre-culture of LT-HSCs prior to the 4-OHT exposure led to the 
increased colony numbers (Figure 13B). Transgene activation in LT-HSCs occurred 
at a very low frequency as revealed by qRT-PCR analysis. The best results were 
achieved with pre-incubation in Stemspan for 16 hours followed by 1-hour exposure 
to 500nM 4-OHT (Figure 13C). Low efficiency could be explained by the fact, that 
Cre recombinase activity is cell-cycle dependent (mainly in late S to M phase) (Jo 
et al., 2003), whereas LT-HSCs are mainly dormant and arrested in G0 phase 
(Nakamura-Ishizu et al., 2014; Wilson et al., 2008). Live cell imaging demonstrated, 
that the first division of LT-HSC in vitro takes on average 45-50 hours (Haetscher et 
al., 2015). In conclusion, we find in vitro approach not feasible due to the low 
efficiency and technical limitations. 
For the in vivo part, we again FACS sorted non-induced LT-HSCs from donor mice 
and transplanted them into lethally irradiated BL6 recipients, that were either pre-
treated with tamoxifen at various time, or their diet was supplemented with 
tamoxifen-containing food (Figure 14A) (Reinert et al., 2012; Wilson et al., 2014). 
Follow-up of transplanted mice by measuring serial blood counts and GFP 
chimerism revealed, that some of the mice developed MPN. Disease initiation 
positively correlated with increasing tamoxifen dose and time course of the 
administration. However, high tamoxifen dose also had a negative effect on survival 
(data not shown). After several trials, we established the final dose that induces 
HSCs in vivo with sufficient efficiency and does not cause any lethality: a single dose 
of 5mg of tamoxifen administered at the time of transplantation (Figure 14B, green 
group). Although tamoxifen-supplemented diet also showed high efficiency, it could 
potentially lead to the high intergroup variabilities. We plan to use this setup in 
elucidating the role of biased stem cells and bone marrow microenvironment in 
disease initiation and progression. 
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Figure 14. Activation of LT-HSC by 4-OHT in vivo. A) Experimental setup describing the isolation of LT-HSC 
population (defined as Lin-, Sca-1+, c-kit+, CD150+, CD48- subset) and subsequent transplantation into 
tamoxifen-pre-treated lethally irradiated recipients together with wildtype whole bone marrow competitors. Each 
circle represents a single tamoxifen injection with the number indicating the tamoxifen dose in milligrams. Color 
corresponds to the different treatment groups displayed in B.  Axis illustrates the time of tamoxifen dosing with 
respect to the transplantation that is displayed as 0. B) Blood parameters and respective chimerism at week 18 
post transplantation. The grey-shaded area represents the normal reference range. Colors for different groups 
correspond to different treatment regimens displayed in A. 
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2.3.2 Tracking MPN initiation in situ 	
Our lab previously showed that a single JAK2 V617F hematopoietic stem cell is 
capable of initiating and driving the MPN disease (Lundberg et al., 2014). However, 
the majority of studies in the hematopoietic stem cell field are using transplantation 
of cells into lethally irradiated animals. This procedure wipes out the recipient's bone 
marrow niche and creates cytokine release syndrome, that favors the engraftment 
of transplanted stem cells and possibly overestimates the disease-initiating capacity 
of JAK2 V617F stem cells.  
To overcome this limitation, we used Confetti reporter system that allows for tracking 
of clonal stem cell origin in situ. Confetti mouse strain has a transgene cassette 
knocked-in in Rosa26 locus under the control of Cre recombinase. This cassette 
contains 4 fluorophores (CFP-GFP-YFP-RFP) that are randomly activated upon Cre 
administration (Schepers et al., 2012; Snippert et al., 2010). In a homozygous state, 
the cassette can produce up to 10 different color combinations (Baggiolini et al., 
2015). Crossing this strain with our JAK2 V617F model allows tagging the disease-
initiating cells fluorescently. We aimed for a limiting dose of tamoxifen to induce only 
a few stem cells to have each stem cell labeled with a different color. Double 
transgenic mice SclCreER; JAK2 V617Ffl/+; Confettifl/fl were induced by single 
injection with various tamoxifen dosage. 
 
 
 
 
Figure 15. Blood parameters and spleen weight of SclCreER; JAK2 V617Ffl/+; Confettifl/fl mice. Blood 
parameters in A) and spleen weight in B) of SclCreER; JAK2 V617Ffl/+; Confettifl/fl mice treated with a single 
tamoxifen injection. The grey-shaded area represents the normal reference range. 
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We monitored the disease progression by measuring serial blood counts, 
composition and frequency of different fluorescently labeled clones by flow 
cytometry. We could observe a dose-response, as mice with the highest tamoxifen 
dose developed the most severe disease (Figure 15A and 15B) and had the highest 
proportion of cells fluorescently tagged (Figure 16A). Interestingly, increasing the 
dose from 2mg to 5mg of tamoxifen did not lead to a further increase in the number 
of activated cells (Figure 16A). Since we were able to detect labeled cells 40 weeks 
after the tamoxifen dosing, we assume that also long-term repopulating stem cell 
and progenitor compartment was targeted by the tamoxifen induction (Figure 16A-
C). 
 
 
 
 
 
Figure 16. The frequency of different color combinations in SclCreER; JAK2 V617Ffl/+; Confettifl/fl mice 40 weeks 
after the tamoxifen injection of Lin- subset in bone marrow (BM) and spleen (SPL). The total frequency of 
recombined cells (A), the total frequency of color combinations (B) and the relative frequency of color 
combinations (C) is shown. In A, an average of the group (2-3 mice) is plotted, whereas in B and C each bar 
represents an individual mouse.  
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Surprisingly, we observed a bias in fluorophore activation, as not all colors were 
detected with a similar frequency. RFP and YFP represented ~ 70% of activated 
cells, and single colors were activated with higher 
efficiency than the double color combinations 
(Figure 16B and 16C). This phenomenon was 
reported before and currently, there is no 
explanation for it (Baggiolini et al., 2015).  More 
importantly, we could detect human JAK2 
expression (transgenic V617F allele) in the 
fluorescent-negative subset of Lin- population, 
meaning, that 2 transgenes we combined in this 
mouse model have a different threshold of 
activation (Figure 17). JAK2 V617F transgene 
being more sensitive to tamoxifen yields cells with 
activated human JAK2, but without a fluorescent 
label. Two abovementioned observations 
demonstrate that the tested model is not suitable 
for intended studies of MPN initiation from single 
HSPC cell. Thus, different approaches, such as 
molecular barcoding need to be explored.  
 
 
 
 
  
 
 	
  
Figure 17. Human JAK2 expression in 
c-kit+; XFP- compartment. qRT-PCR 
analysis of human JAK2 expression in 
bone marrow (BM) and spleen (SPL) 
of mice treated with low tamoxifen 
dose together with the bone marrow of 
JAK2 V617F mouse (BM VF) and 
wildtype mouse (BM WT) that were 
used as controls.  
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3 Discussion 		
3.1 EPO gene mutation and erythrocytosis 	
Erythropoietin is to date the only identified humoral factor regulating erythropoiesis. 
Therefore, mutations in the gene coding for EPO are thought to disturb this 
regulation. Indeed, Arg150Gln substitution leading to loss-of-function and causing 
Diamond-Blackfan-like anemia was reported (Kim et al., 2017). Conversely, gain-
of-function mutations in the EPO gene causing erythrocytosis have not been 
described yet.  
Earlier this year we described a novel gain-of-function mutation in the EPO gene 
causing an inherited form of erythrocytosis and elucidated the molecular mechanism 
of the disease pathogenesis (Zmajkovic et al., 2018). We identified the candidate 
mutation based on the genetic linkage with a LOD score of 3.3 for the locus on 
chromosome 7q21, in a pedigree with 10 affected family members. This mutation, a 
heterozygous deletion of a G nucleotide at a position 32, introduces a frameshift in 
exon 2 that interrupts translation of the main EPO mRNA (P1 transcript). It appeared 
to be a loss-of-function mutation at first sight. However, it also initiates excess 
production of erythropoietin from alternative non-coding mRNAs (P2 transcripts) 
located in intron 1 of the EPO gene. P2 transcripts produce biologically active EPO 
due to the frameshift inflicted by DG that provides a bridge to the open reading frame 
coding for physiological EPO. Therefore, mutations in EPO should be considered in 
the search for causes of secondary erythrocytosis. Finally, our study also 
demonstrates the usefulness of CRISPR/Cas9 genome editing in elucidating the 
molecular mechanisms of rare diseases.  
P2 transcripts were the predominant mRNA species in the liver, whereas P1 
transcripts were mainly detected in RNA from the kidney. Thus, we suspect that the 
excessive amounts of EPO in the affected family members are coming from the liver. 
Glycosylation of EPO is critical for maintaining longer half-life in the serum 
(Goldwasser et al., 1974). A method to determine the overall glycosylation pattern 
of EPO, based on the chromatographic separation of the EPO isoforms was 
developed (Lönnberg et al., 2012). Intriguingly, EPO was significantly more 
glycosylated in the human umbilical cord plasma samples than in the samples from 
the peripheral blood (de Seigneux et al., 2016). Since EPO in the human umbilical 
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cord plasma is of the hepatic origin and EPO in the peripheral blood plasma of a 
renal origin, it seems that these two organs glycosylate EPO differently.  Thus, it 
would be interesting to measure the glycosylation pattern of EPO in affected and 
non-affected family members, as we would expect that affected family members with 
the majority of EPO produced in the liver would have higher glycosylation level 
compared to the non-affected family members.  
Erythropoietin executes a fundamental role in the organism, and this importance is 
also reflected in the conservation of its mRNA sequence among the species. 
Noteworthy, there is also conservation of certain non-coding regions of EPO 
between human and mouse, including the intron 1, with overall homology over 65% 
(Shoemaker and Mitsock, 1986). It was suggested that this region might exhibit a 
regulatory function (Imagawa et al., 1991; Madan et al., 1995; Shoemaker and 
Mitsock, 1986).  
Interestingly, gene regulatory elements are mostly found within the 5’-most introns 
(Beaulieu et al., 2011; Bianchi et al., 2009; Coulon et al., 2010; Gaunitz et al., 2005; 
2004; Kaneko et al., 2014; Ott et al., 2009; Scohy et al., 2000; Tourmente et al., 
1993). Furthermore, intronic RNAs constitute the major fraction of the non-coding 
RNA and contain a large number of potential endogenous siRNAs (Rearick et al., 
2011; St Laurent et al., 2012).  
 
 
Figure 18.  Intron 1 of the EPO gene is conserved amongst vertebrates. The upper panel shows UCSC tracks 
PhyloP and PhastCons displaying the conservation of EPO genomic sequence amongst 100 vertebrates. The 
lower panel is a zoom in the region of intron 1, where GATA boxes within the putative promoter in orange and 
P2 transcriptional start side in red reside.  
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The physiological function of wild-type P2 transcripts is currently unknown, but it 
seems likely that they do have a function because one of the conserved regions 
within intron 1 contains P2 transcriptional start site (Figure 18). We found that the 
long form of EPO P2 transcript is vastly overexpressed in the adult human liver 
compared to the kidney. The liver is considered to be the primary organ of the EPO 
production in the embryonic development. Around the birth, EPO production 
gradually moves to kidneys that become the primary site of the production of EPO 
in adult life. Although this switch is well documented in multiple species (Bondurant 
et al., 1991; Dame et al., 1998; Eckardt et al., 1992; Peschle et al., 1975; Zanjani et 
al., 1981), molecular mechanisms leading to this switch remain elusive. It was 
suggested, that the spatio-temporal expression of GATA transcription factors may 
play a role in this process (Weidemann and Johnson, 2009).  
GATA proteins share related Cys-X2-Cys-X17-Cys-X2-Cys (where X represents any 
amino acid residue) zinc-finger DNA-binding domains among mammals that bind to 
the consensus motif 5′-(A/T)GATA(A/G)-3′ (Simon, 1995) (Simon, 1995), and play 
critical roles in cell growth and differentiation (Lentjes et al., 2016). In the core 
promoter region of erythropoietin, a GATA factor-binding motif (GATA box) with the 
core sequence AGATAACA resides. Intron 1 putative promoter also contains two 
consecutive GATA boxes TGATAAGCTGATAACC. It was reported that human 
GATA-1, GATA-2, and GATA-3 are able to bind to the core EPO promoter sequence, 
inhibit the formation of pre-initiation complexes, and thereby reduce the expression 
of EPO mRNA in Hep3B cells (Aird et al., 1994; Imagawa et al., 1997; 2002). In 
addition, GATA-2 and GATA-3 were demonstrated to constitutively repress EPO 
expression in renal tubular cells in the kidney in vivo (Obara et al., 2008). Thus, it 
was proposed that GATA box acts as a negative regulatory element, repressing the 
EPO transcription during normoxia. Under hypoxic conditions, GATA binding 
markedly decreases, which allows for a significant increase in EPO gene expression. 
In contrast, GATA-4 was proposed to have a positive effect on EPO expression in 
Hep3B cells, since knockdown of GATA-4 negatively regulated EPO mRNA levels 
(Dame et al., 2004). We looked at the distribution of GATA transcripts in human 
kidney and liver samples in the publicly available RNASeq database of ProteinAtlas 
(Uhlen et al., 2017) and also analyzed GATA expression in kidney and liver 
specimens by qRT-PCR (Figure 19). 
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In both cases, we found that GATA-3 and GATA-4 showed tissue-specific 
expression pattern. GATA-3 was expressed in the kidney and not in the liver, 
whereas GATA-4 was expressed in the liver, but not in the kidney. In line with this 
observations, GATA-3 knockout in the mouse is embryonically lethal at day E12.5, 
due to the aberrations in fetal liver hematopoiesis (Pandolfi et al., 1995) and renal 
morphogenesis defects (Grote et al., 2006). Furthermore, individuals with GATA-3 
haploinsufficiency suffer from renal anomalies as a part of HDR Syndrome 
Figure 19.  The upper graph shows the expression of GATA proteins in human kidney and liver as determined 
by RNAseq (ProteinAtlas). The lower graph displays the expression of GATA proteins in human kidney and 
liver as determined by qRT-PCR.  
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(Hypoparathyroidism, Sensorineural Deafness and Renal Disease) (Van Esch et al., 
2000). Disruption of GATA-4 also leads to the embryonic lethality at day E9.5 due 
to the heart morphogenesis defects and defects in the development of embryonic 
liver (Kuo et al., 1997; Watt et al., 2004).  
Based on the evidence above, we hypothesize that EPO P2 transcripts are silencing 
the expression of P1-coded erythropoietin in hepatocytes after birth. Liver-restricted 
expression of P2 transcripts may be positively regulated by GATA-4 or negatively 
regulated by GATA-3 transcription factors. To get a deeper understanding of this 
regulation, we aimed to generate a Hep3B cell line, knocked-out for EPO P2 
transcripts, by employing the CRISPR/Cas9 genome editing approach. We pursued 
to knock-out two GATA-boxes of the P2 putative promoter in the intron 1. The 
schematics of targeting of the locus by one of gRNAs is shown in Figure 20.   
 
 
 
We were able to generate multiple single-cell clones with different indels in the 
GATA-box region (Figure 21). We first plan to confirm that the EPO P2 putative 
promoter knock-out clones do not express P2 transcripts. Next, to test our 
hypothesis, that EPO P2 transcripts might be responsible for silencing the 
expression of EPO in hepatocytes, we will measure EPO production in cell 
supernatants by ELISA. If our hypothesis is correct, we expect that the expression 
of EPO from the P1 promoter will increase in these cells.  
It could also well be, that the P2 transcripts regulate the function of other genes in 
the form of a long non-coding RNA, or a short peptide produced by the translation 
of P2 transcript (Anderson et al., 2015; Kondo et al., 2010; Magny et al., 2013; 
Nelson et al., 2016; Pauli et al., 2014). If we do not see an effect on the 
erythropoietin production, we aim to identify other potential targets of P2 transcripts 
by RNAseq. To elucidate the potential contribution of GATA proteins in the spatially-
restricted expression of P2 transcripts, we will perform knock-down of GATA-4 by 
siRNA and overexpression of GATA-3 in Hep3B cell line. We also plan to perform 
EPO intron 1 5’
3’ 5’
3’GTGCCAGTGGAGAGGAAGCTGATAAGCTGATAACCTGGGCGCTGGAGCCACCAC
CACGGTCACCTCTCCTTCGACTATTCGACTATTGGACCCGCGACCTCGGTGGTG
sgRNA #3
Figure 20. An example of gRNA targeting GATA boxes located within the intron 1 of EPO.  Single-guide RNA 
targeting sequence is depicted in light blue and protospacer adjacent motif (PAM) in orange. The arrow shows 
the cut site. GATA boxes are framed in red.  
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CHIP experiments to identify, whether GATA proteins bind to the putative promoter 
in intron 1 of the EPO gene.  
3.2 THPO gene and thrombocytosis 
Thrombopoietin is the primary cytokine regulating the proliferation of megakaryocyte 
progenitors expressed by liver hepatocytes. Until recently, TPO production was 
sought to be constitutive (Stoffel et al., 1995), with TPO plasma levels regulated by 
the uptake of the TPO by megakaryocytes and platelets (Broudy et al., 1997; Fielder 
et al., 1996; 1997). However, multiple reports suggest that the regulation of serum 
TPO levels is much more complex and include IL-6 signaling (Burmester et al., 2005; 
Kaser et al., 2001; Wolber et al., 2001), clearance of aged platelets through Ashwell-
Morell receptor (Grozovsky et al., 2015) and glycoprotein receptor GPIba (Xu et al., 
2018). On the translational level, steady-state serum TPO levels are maintained by 
the translational inhibition mechanism (Ghilardi et al., 1998). Disruption of this 
Figure 21. Sequencing chromatograms of Hep3B single cell clones edited with CRISPR/Cas9. Grey-shaded 
areas mark the out-of-frame sequence due to the indels generated by CRISPR/Cas9. A red arrow with red dotted 
lines marks the GATA box region. Both forward and reverse reads are displayed for each clone. Non-targeting 
gRNA is a control gRNA with the random sequence that is not compatible with any region in the human genome. 
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regulation by different mutations within 5’-untranslated region causes hereditary 
thrombocythemia (Ghilardi and Skoda, 1999; Ghilardi et al., 1999; Kondo et al., 
1998; Liu et al., 2008; Wiestner et al., 1998).  
Here, we describe a novel activating mutation in the THPO gene leading to the 
hereditary thrombocytosis. G>T substitution resides in the 5’-UTR and disrupts the 
Kozak consensus sequence of uORF7, the main upstream open reading frame 
involved in the negative regulation of THPO mRNA translation. Mutations in the 
Kozak sequence were previously reported to be involved in the disease 
pathogenesis of β-thalassemia (De Angioletti et al., 2004), congenital heart defects 
(Mohan et al., 2014), androgen insensitivity syndrome (Choong et al., 1996), ataxia 
(Usuki, 2000), and breast cancer (Signori et al., 2001). We found that G>T 
transversion leads to the increase of TPO protein in the cell culture supernatant of 
HEK293 cells transfected with THPO G480T construct, in comparison to the THPO 
wildtype control. Furthermore, in vitro translation of the THPO G480T mRNA 
produced more TPO protein than the translation of THPO wildtype mRNA.  
Our results demonstrate that this single nucleotide variant decreases the translation 
initiation rate from uORF7. This allows ribosomes to initiate the translation from 
AUG8, a start codon of TPO polypeptide. Interestingly, G480T mutation shows a 
weak phenotype compared to the previously reported mutations. This observation 
could be explained by the fact that the guanine at +4 position is only one of the 
required residues of the Kozak consensus sequence (Kozak, 2002).  
3.3 Concluding remarks 
In conclusion, we identified a novel mutation in the erythropoietin gene that causes 
an inherited form of erythrocytosis. We discovered an unexpected mode of action 
of this mutation, in which an alternative non-coding mRNAs originating in intron 1 of 
the EPO gene connect to the EPO open reading frame due to the frameshift inflicted 
by the mutation and produce the excessive quantities of EPO protein. Alternative 
transcripts originating in intron 1 of other genes may be involved in the pathogenesis 
of the diseases, as recently demonstrated for the VHL gene and erythrocytosis 
(Lenglet et al., 2018). Our finding has a direct clinical impact since the sequencing 
of the EPO gene should be implemented into the standard diagnostic pipeline for 
idiopathic erythrocytosis. Moreover, the results of our study suggest that intron 1 
transcripts may regulate EPO expression in the liver, a process that is to date poorly 
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understood. Lastly, our study nicely demonstrates the usefulness and suitability of 
genome-editing techniques in identifying the molecular mechanisms of rare 
disorders.  
We also described a novel gain-of-function variant in the thrombopoietin gene that 
gives rise to the familial thrombocytosis. This novel variant modifies the Kozak 
sequence of the upstream open reading frame, disrupts the negative regulation of 
THPO expression, and leads to the elevated serum TPO levels.  
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2008-2010        Master of Science with honors, Comenius University in Bratislava, Slovakia  
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(fellowship from the National Scholarship Agency of the Slovak Republic) 
 
2004-2007       Bachelor of Science, Comenius University in Bratislava, Slovakia 
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 * equal contribution 
 
Awards and Achievements 
 
2018  Department of Biomedicine Basel Research Prize for the best publication 
 
2018  Bruno Speck Award (Stiftung für Hämatologische Forschung Basel) 
 
2017   “Get on track” scholarship awarded by the University of Basel  
 
2017   Abstract Achievement Award, ASH Annual Meeting 2017 
 
2008  Slovak National Scholarship Agency fellowship to study at Katholieke Universiteit, Leuven 
 
 
Courses and Skills 
 
Laboratory skills: 
• Course in Laboratory Animal Science FELASA Category B (2015) 
• Techniques:  
- mammalian cell culture (adherent and non-adherent cell lines, primary cells), hematopoietic colony-
forming cell assays 
- molecular cloning, CRISPR-mediated gene editing, transfections, single cell cloning 
- Western blotting, qRT-PCR, ELISA, multicolor flow cytometry,  
- mice handling, organ removal, serial blood sampling, i.p. and i.v. injections 
• Databases for experimental animals (PyRAT) and biological samples (Spirit) 
• Online documenting and patenting system (PatentSafe) 
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Soft skills: 
• The Role of Intellectual Property in Life Sciences course (2015)
• Good Scientific Practice workshop (2017)
• Conflict management workshop (2018)
• Writing science articles for Slovak newspapers SME (authored 17 articles online and 12 in print)
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